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AAA1, asthma associated alternatively spliced gene 1
AD, atopic dermatitis
ADAM, a disintegrin and a metalloproteinase
AHR/BHR, airway/bronchial hyperresponsiveness
BAL, bronchoalveolar lavage
b-AR, adrenergic receptor
BPD, bronchopulmonary dysplasia
cAMP/cGMP, cyclic adenosine/guanosine monophosphate
CD, cluster of differentiation
cDNA, complementary deoxyribonucleic acid
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DPP10, dipeptidyl peptidase 10
FCV, forced vital capacity
FEV1, forced expiratory volume in one second
GAPDH, glyceraldehyde 3-phosphate dehydrogenase
GMP/GDP/GTP, guanosine mono/di/triphosphate
GPCR, G protein-coupled receptor
GPRA, G protein-coupled receptor for asthma susceptibility, official name NPSR1
GST, glutathione S-transferase
HLA, human leukocyte antigen
IBD, inflammatory bowel disease
IgE, immunoglobulin E
IL, interleukin
LPS, lipopolysaccharide
LT, leukotriene
MS, multiple sclerosis
mRNA, messenger ribonucleic acid
NPS, neuropeptide S
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PBMC, peripheral blood mononuclear cell
PG, prostaglandin
PHF, plant homeodomain finger protein
RACE, rapid amplification of cDNA ends
RDS, respiratory distress syndrome
RT-PCR, reverse-transcriptase polymerase chain reaction
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis
SMC, smooth muscle cell
SNP, single nucleotide polymorphism
TBS/PBS, Tris/phosphate-buffered saline
TDT, transmission disequilibrium test
Th, T helper cell
TM, transmembrane
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7A. ABSTRACT
The basis of this work was the identification of a genomic region on chromosome 7p14-p15 that
strongly  associated  with  asthma  and  high  serum  total  immunoglobulin  E  (IgE)  in  a  Finnish
founder population from Kainuu. Using a hierarchical genotyping approach the linkage region
was narrowed down until an evolutionary collectively inherited 133-kb haplotype block was
discovered. The results were confirmed in two independent data sets: Asthma families from
Quebec  and  allergy  families  from  North-Karelia.  In  all  the  three  cohorts  studied,  single
nucleotide polymorphisms tagging seven common gene variants (haplotypes) were identified.
Over half of the asthma patients carried three evolutionary closely related susceptibility
haplotypes as opposed to approximately one third of the healthy controls. The risk effects of the
gene variants varied from 1.4 to 2.5.
In the disease-associated region, there was one protein-coding gene named GPRA (G
Protein-coupled Receptor for Asthma susceptibility alias GPR154 and NPSR1) which displayed
extensive alternative splicing. Only the two isoforms with distinct intracellular tail sequences,
GPRA-A and -B, encoded a full-length G protein-coupled receptor with seven transmembrane
regions. Using various techniques, we showed that GPRA is expressed in multiple mucosal
surfaces including epithelial cells throughout the respiratory tract. GPRA-A has additional
expression in respiratory smooth muscle cells. However, in bronchial biopsies with unknown
haplotypes, GPRA-B was upregulated in airways of all patient samples in contrast to the lack of
expression in controls.
Further support for GPRA as a common mediator of inflammation was obtained from a
mouse model of ovalbumin-induced inflammation, where metacholine-induced airway
hyperresponsiveness correlated with elevated GPRA mRNA levels in the lung and increased
GPRA immunostaining in pulmonary macrophages. Expression analyses revealed that a novel
GPRA agonist, Neuropeptide S (NPS), co-localizes with GPRA in human bronchial and colon
epithelia, and in inflammatory cells. In a mouse macrophage cell line, NPS stimulated
phagocytosis of Esterichia coli bacteria indicating a role for GPRA in removal of inhaled
allergens.
The suggested GPRA functions prompted us to study whether GPRA haplotypes associate
with respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) in infants
sharing clinical symptoms with asthma. According to the results, near-term RDS and asthma may
also share the same susceptibility and protective GPRA haplotypes. As in asthma, GPRA-B
isoform expression was induced in bronchial smooth muscle cells in RDS and BPD suggesting a
role for GPRA in bronchial hyperresponsiveness.
In conclusion, the results of the present study suggest that  the dysregulation of the GPRA/NPS
pathway may not only be limited to the individuals carrying the risk variants of the gene but is
also involved in the regulation of immune functions of asthma.
B. INTRODUCTION
Asthma is currently defined as a chronic inflammatory disease of the airways. The inflammation
causes recurrent episodes of wheezing, breathlessness and cough in susceptible individuals. Often
the symptoms are associated with variable airflow limitation that is at least partly reversible and
includes increased airway responsiveness to various stimuli (the National Heart, Lung and Blood
Institute in the United States / World Health Organization 2002).
Asthma is a worldwide disease with variable expression between countries and different
populations within a country. The prevalence of asthma has been increasing worldwide over the
last four decades of the 20th century. Just in recent years, evidence is emerging that this trend has
flattened or even fallen in some countries and populations (von Hertzen and Haahtela 2005).
The current asthma therapies are not cures. The symptoms return soon after the treatment
has been stopped even after long-term therapy. The mechanisms involved in the persistence of
inflammation  are  poorly  understood.  It  is  still  unknown,  why some patients  suffer  from severe
life-threatening disease, whereas the management of the disease is easier with others. Thus, there
is a constant demand for knowledge and new therapies for asthma.
Although environmental factors such as life style and allergen exposure are undoubtedly
risk factors for asthma, both familial and twin studies support a definite role for inherited features
in the disease mechanism (Harris et al.1997, Panhuysen et al.1998, Koppelman et al.1999,
Räsänen et al. 2000). Traditionally, genome-wide screening and candidate gene approach have
been the two strategies in mapping the susceptibility alleles for asthma-related traits. In the
former, markers evenly distributed across the whole genome are used to identify novel loci
involved in the genetic susceptibility of the disease in an unbiased manner. In the latter,
knowledge of genome-wide scans and molecules involved in the pathogenesis of asthma are
utilized to study appropriate candidate gene regions. Only recently, several groups have
progressed from broad linkage regions to identification of positional candidate genes for asthma.
These approaches have exposed totally new avenues for asthma research.
The basis of this work was the identification of a genomic region on chromosome 7p14-
p15 that strongly associated with asthma and high serum total immunoglobulin E (IgE) in a
founder population recruited from Kainuu province of Finland (Laitinen et al. 2001). Further
finemapping of the linkage region exposed a 133 kb segment, which could be divided into three
susceptibility and four neutral/protective haplotypes (Laitinen et al. 2004). Utilization of
computer algorithms for gene prediction over the disease-associated region revealed two
previously uncharacterized genes, GPRA (G Protein coupled Receptor for Asthma susceptibility)
and AAA1 (Asthma Associated Alternatively spliced gene 1), with unknown biological functions.
In 2005, two independent reports replicated the genetic findings in large European cohorts of up
to 5000 study subjects (Melen et al. 2005, Kormann et al. 2005). Most recently, a single
nonsynonymous polymorphism in the GPRA gene was associated with increased susceptibility to
methacholine-induced bronchial hyperresponsiveness in Chinese population (Feng et al. 2006)
9suggesting GPRA to become the prime candidate for the linkage observed within the 7p14.3
region.
Other groups were studying GPRA functions in parallel with the work carried out in our
group. Vassilatis and co-workers identified novel G protein-coupled receptors (GPCRs) including
GPRA by sequence pattern mining in a systematic screening approach to construct a phylogenetic
tree for GPCRs (Vassilatis et al. 2003). Gupte and coworkers utilized a chimeric receptor
approach where the intracellular signaling parts of the vasopressin V1a receptor were joined to
the C-terminal portion of GPRA (Gupte et al. 2004). The authors showed activation of the
chimeric receptor by arginine vasopressin and suggested that GPRA has dual signalling
properties by coupling to both Gq and Gs pathways (Gupte et al. 2004). While the authors where
processing their manuscript, a patent application reported identification of a linear 20-residue
proteolytic fragment peptide that acted as an endogenous ligand for GPRA (Mori et. al 2003).
These findings paved the way for functional studies utilizing the novel GPRA agonist named
Neuropeptide S (NPS) (Xu et al. 2004). The main objective of this study was to clarify the role of
GPRA in the pathogenesis of asthma to reveal novel disease mechanisms, and possibly, to find
novel treatment opportunities for the disease.
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C. REVIEW OF THE LITERATURE
1. CLINICAL FEATURES OF ASTHMA
1.1 Definition
In 2002, the National Heart, Lung and Blood Institute in the United States published the
following definition of asthma: “Asthma is a chronic inflammatory disorder of the airways in
which many cells and cellular elements play a role, in particular mast cells, eosinophils, T-
lymphocytes, macrophages, neutrophils and epithelial cells. In susceptible individuals, this
inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and
coughing, particularly at night or in the early morning. These episodes are usually associated
with widespread but variable airflow obstruction that is often reversible either spontaneously or
with treatment. The inflammation also causes an associated increase in the existing bronchial
responsiveness to a variety of stimuli.” The symptoms can be induced e.g. by viral infections in
childhood, exercise, or inhalation of cold air and allergens. The typical histological alterations in
the airway wall include basement membrane thickening, goblet cell hyperplasia, as well as
epithelial damage and SMC hypertrophy. These changes are often termed “airway remodelling”
(Davies et al. 2003). However, none of the single features or group of features can be defined as
common to all asthmatics. Both environmental and genetic factors attribute to the progress of the
disease.
The clinical diagnosis of asthma is accomplished by demonstrating reversible airflow
obstruction on spirometry. This can be carried out using sequential measurements of peak
expiratory flow, forced expiratory volume in one second (FEV1), forced vital capacity (FVC),
and FEV1/FVC before and after inhalation of a short-acting bronchodilator. Clinically significant
reversibility is defined as a significant increase of more than 12 % or 200 ml in FEV1 after
inhalation of a short-acting bronchodilator or treatment with corticosteroids (the National Heart,
Lung and Blood Institute in the United States / World Health Organization 2002).
1.2 Prevalence
The lack of a generally accepted asthma definition for epidemiological studies complicates the
comparison of studies on time trends in asthma prevalence. According to the estimations, asthma
affects up to 20% of children and 5-12% of adults in industrialized countries (ISAAC Steering
Committee 1998). The prevalence of asthma has been increasing worldwide over the last four
decades of the 20th century, although evidence is emerging that in recent years this trend has
flattened or fallen in some countries and populations (Flemming et al. 2000, Verlato et al. 2003,
Braun-Fahrländer et al. 2004, von Hertzen and Haahtela 2005). However, a nationwide study on
time trends in prevalence of asthma and allergy in Finnish young men at call-up for military
service during the years 1966-2003 found no evidence of a reduction in the prevalence of either
asthma or allergic rhinitis (Latvala et al. 2005). Asthma has become milder or more controlled
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disease during the past 15 years, but still remains the most common chronic disease among
children. Fortunately, the prevalence of symptoms in asthmatic children decreases towards
adulthood.
1.3 Risk factors
1.3.1 Atopy
The term “atopy” is commonly defined as genetic predisposition for immunoglobulin E (IgE) -
mediated responses such as skin reactions to minute amounts of common allergens (Johansson et
al. 2004). Atopy is the strongest identifiable predisposing factor to the developing asthma and
more than 80% of asthmatics have an atopic background. However, also non-atopic asthma
exists. Strategies that abolish allergen-specific IgE responses (Barnes 1996, Creticos et al. 1996,
Adkinson et al. 1997) or that remove total serum IgE (Holgate et al. 2004) are not of complete
efficacy for asthma treatment. Although most of the children with asthma are atopic,
approximately 10% of patients with childhood asthma have normal levels of total IgE and do not
have specific IgE responses to common allergens (Romagnani 2004). Typically, these non-atopic
patients display variable but incomplete reversibility of airway obstruction, and are clinically
difficult to distinguish from atopic patients (McConnell and Holgate 2000). The two types of
asthma probably represent different conditions with distinct disease mechanisms and genetic
backgrounds.
The common syndrome of atopic diseases also includes atopic dermatitis (AD) and hay
fever (allergic rhinitis), which are risk factors for asthma (Spergel 2005). AD, also called eczema,
is a chronically relapsing inflammatory skin disease characterized by dryness of the skin and
itching, which results in scratching and excoriations. In a German atopy study containing 1300
children, patients with AD showed increased risk for asthma at the age of seven, whereas patients
with AD and no wheezing during the first 3 years did not. Thus, the authors proposed that AD
may not develop into asthma, but is part of a syndrome consisting of both diseases (Lau et al.
2002). In a questionary consisting of over 90000 individuals, patients with rhinitis had an
increased risk for asthma and lower airway reactivity when compared with patients without
rhinitis (Leynaert et al. 2004). In contrast to asthma, allergic rhinitis appears to be associated
primarily with skin test reactions to common aeroallergens, independent of the serum IgE level. It
is defined as an epithelial inflammation of the nose, and characterized by nasal congestion,
rhinorrhoea, sneezing and itching.
1.3.2 Genetics
Both familial and twin studies support a role for inherited features in the disease mechanisms of
asthma (Harris et al.1997, Panhuysen et al.1998, Koppelman et al. 1999, Räsänen et al. 2000).
First, asthma and atopic diseases cluster in families. The risk that a first-degree family member of
a patient with asthma will develop asthma has been calculated to be less than two to almost six
12
times higher than the risk for individuals in the general population. Because the presence of
aggregation among related individuals may indicate either shared genes or a common household
environment, the genetic influence on asthma has also been sorted out by using twin studies and
segregation analyses. Monozygotic twins have identical genetic make-up whereas dizygotic twins
share approximately 50% of their genes. If genes were influenced by a particular trait,
monozygotic twins should resemble each other to a greater extent than dizygotic twins because of
the  greater  genetic  similarity.  Regarding  to  asthma,  the  first  large  twin  study  was  published  in
1971 on a Swedish population of 6996 twin pairs (Edfors-Lubs et al. 1971). The results showed
that the concordance for self-reported asthma of monozytic twins and dizygotic was 19.0% and
4.8%, respectively, illustrating the genetic influence. In the Finnish twin cohort, the heritability of
asthma was estimated to be 35.6% (Nieminen et al. 1991). Among the younger twin cohort, the
genetic effect accounted for 79% of the variance in the development of asthma (Laitinen et al.
1998). These studies provide strong evidence for hereditary basis in the disease mechanisms,
although the genetic susceptibility for asthma is unlikely to explain the observed increase in the
prevalence of asthma. Environmental influences in asthma are established with the finding that
occasionally in monozygotic twins only one of the twins is affected by the disease. Genetic
studies have also demonstrated that atopy and bronchial hyperresponsiveness (BHR) have
different patterns of inheritance. Whereas the ability to produce IgE is regulated at genetic level,
the specificity of the IgE response may mainly be affected by the environment.
1.3.3 Environmental factors
Asthma is a worldwide disease with variable expression between countries and between different
populations in a country. Its prevalence is generally higher in the western countries than in the
developing countries indicating that western lifestyle with indoor environment, diet, air pollution
and psychological stress might play a role in the onset of the disease. This has given rise to the
widely debated theory called “hygiene hypothesis” stating that exposure to microbes in childhood
protects against asthma. The four main environmental candidates for the elevated asthma
prevalence  in  the  western  countries  are  changes  in  exposure  to  infectious  diseases  in  early
childhood, environmental pollution, allergen levels, and dietary changes (Arruda et al. 2005). The
length and type of exposure to infectious agents as well as the time when it happens have been
shown either to promote or to suppress an inflammatory process and influence on a subsequent
history of asthma. Childhood on a traditional farm seems to confer protection against the
development of asthma and atopy suggesting that continuous inhalation of lipopolysaccharide
(LPS) might somehow dampen the harmful immune responses (von Ehrenstein et al. 2000,
Riedler et al. 2001, Braun-Fahrländer et al. 2002). Exposure to environmental pollution could
worsen the expression of atopy and asthma, but the best evidence, however, shows the opposite.
For example, children in the cities of Halle and Leipzich in the former East Germany had lower
prevalence of atopy and asthma when compared with ethnically matched population in Munich
from the western part of the country with cleaner air. In the former population, children had,
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however, a higher overall prevalence of respiratory diseases than in the latter. Nevertheless, those
diseases were not of allergic origin (von Mutius et al. 1994). Five years after reunification,
allergy rates had risen up in East Germany and the allergic sensitization rates had equalized to the
same extent to the western part of the country (Weiland et al. 1999). A similar west-east trend in
childhood allergic sensitization, hay fever, and eczema was observed in a recent study reporting
higher rates of allergy among Finnish children in North-Karelia when compared to their adjacent
Russian counterparts (von Hertzen et al. 2006). As a hint of the influence of the western nutrition,
there is even a study suggesting that frequent consumption of hamburgers shows a dose-
dependent association with asthma symptoms (Wickens et al. 2005). Thus, these findings may
indicate that locally operating factors such as pollutant exposure, diet, and respiratory virus
infections may indeed predispose individuals to asthma.
1.3.4 Neonatal characteristics
Epidemiological studies have repeatedly reported an increased risk of asthma or wheezing
disease  among  preterm  children  with  respiratory  distress  syndrome  (RDS)  or  RDS  and
subsequent bronchopulmonary dysplasia (BPD) (Schaubel et al. 1996, Evans et al. 1998, Smith
2003). In a study utilizing data from a provincial health organization to evaluate the effect of
birth characteristics on asthma incidence and hospitalization for asthma during the age of 0-4,
several neonatal characteristics were important determinants for the risk of physician-diagnosed
preschool asthma (Schaubel et al. 1996). Significant association with preschool asthma included
male gender, low birthweight and prematurity. RDS in the presence or absence of BPD showed
associations both with asthma incidence and hospitalization due to asthma. Other perinatal factors
that associate with the development of asthma and atopic diseases include low birth weight,
prenatal exposure to tobacco smoke, severe respiratory infection in the first year of life and lack
of breast feeding (Young et al. 1991, Evans et al. 1998, Friedman and Zeiger 2005).
1.4 Pathogenesis
According to the current consensus view high IgE-levels derived as a result of cluster of
differentiation (CD) 4+ T helper type 2 (Th2) cell responses account for the pathogenesis of
atopic diseases. Th2 cells promote B-cell derived IgE production (Kay 2001). Allergen-specific
IgE binds to its high-affinity Fc receptor (Fc?RI)  on  mast  cells  and  basophils  and  low  affinity
receptors (Fc?RII or CD23) on T -lymphocytes, eosinophils, and antigen presenting cells, such as
B-cells, monocytes and dendritic cells. The immediate symptoms of asthma are triggered, when
allergens penetrated through the bronchial epithelium induce crosslinking of Fc?RI. Subsequent
mast-cell degranulation releases pro-inflammatory molecules and potent bronchoconstrictors
such as histamine, cysteinyl leukotriene (LT) C4 and prostaglandin (PG) D2 (Cookson 2004).
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The development of allergic asthma can be separated into three phases (Elsner et al. 2004).
1) In the initiation phase, genetic predisposition to atopy predominates and the development
of IgE antibodies against environmental antigens occurs. According to the hygiene
hypothesis, antigen presentation in susceptible individuals results in polarized T-cell
differentiation towards a Th2 instead of an opposite Th1 phenotype (Wills-Karp et al.
2001, Yazdanbakhsh et al. 2002). The Th2 cells secrete preferably interleukins (ILs) 4, 5,
9 and 13, and the Th1 cells interferon-? and IL-2. The effective IgE production by B cells
depends on support by Th2 cells (Kay 2001).
2) In the propagation phase of allergic asthma, Th2-polarized T lymphocytes and eosinophils
infiltrate the airways, leading to a chronic inflammatory state. IL-4 is essential for T-cell
survival and expansion, IL-5 for eosinophil maturation and IL-13 for mucus production
and SMC contraction. Increasing body of evidence also shows the importance of
chemokines and their receptors in the mechanisms of recruiting eosinophils into the lung
and maintaining local Th2-cell dominance (section 3.3.2).
3) In the final effector phase of the disease, the inflammation leads to edema of the lung
tissue along with complement activation, and cell extravasation (Humbles et al. 2000).
The production of mediators of chronic inflammation leads to airway
hyperresponsiveness (AHR), mucus hypersecretion and structural changes of airway
architecture. Loss of bronchodilators such as PGE2 and nitric oxide secreted by
epithelium also contribute to AHR in allergic asthma. Eosinophils are able to damage the
epithelium due to the release of reactive oxygen species and their  basic proteins such as
eosinophil cationic protein and major basic protein (Andreadis et al. 2003). These
compounds are also known to cause epithelial shedding, which exposes sensory nerve
endings  to  the  airway  lumen  (Gleich  1988).  Afferent  sensory  nerve  endings  are  also
involved in central reflex bronchoconstriction upon stimulation by inflammatory
mediators such as histamine, adenosine and endothelin-1 (Coleridge et al. 1989, Riccio et
al. 1995). Eosinophils also secrete cytokines such as transforming growth factor-?,
epidermal growth factor and IL-13. Both the toxic compounds and cytokines promote
smooth muscle thickening, AHR and mucus production in allergic asthma.
2. FINDING GENES FOR ASTHMA SUSCEPTIBILITY
In asthma, the susceptibility alleles have relatively high population frequencies, but not everyone
with the susceptibility alleles is affected by the disease (reduced penetrance). Because clinically
similar  phenotype  may also  result  from a  different  set  of  genes  or  environmental  exposure,  the
risk effects are expected to be modest as a maximum (Lander and Kruglyak 1995). In most
genetic studies, self-reported questionnaires in addition to reported doctor’s diagnosis of asthma,
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bronchial hyperresponsiveness, or combinations of these parameters are used for definition of
asthma. Because of the lack of a clearly defined asthma phenotype, additional quantitative traits
(intermediate phenotypes) such as serum total and allergen specific immunoglobulin E levels,
blood eosinophil count and bronchial peak flow variability are commonly used as surrogate
markers (Martinez et al. 1997). Recent studies have shown that global microarray gene-
expression approaches might allow novel asthma candidate genes to be identified. However, the
hypothesis-independent genome-wide search and the hypothesis-dependent candidate-gene
approach have traditionally been, and still exist, as the two basic methods in the genetic asthma
research (Lander and Schork 1994). Regarding the complex and heterogeneous etiopathogenesis
of asthma, it is not surprising that numerous genes have been reported. Because many genes with
individually small effects are likely to contribute to the risk, replication of the linkage results and
association studies has not been trouble-free. Utilization of larger sample numbers in the study
cohorts as well as consideration of multiple gene variants and haplotypes in the latest studies
might have reduced the possibility of false association results. The development and utilization of
more advanced software platforms for association analyses will be useful in gathering novel data
concerning the interaction between the susceptibility genes.
2.1 Genome-wide linkage studies
In genome wide scans, markers evenly distributed across the genome are genotyped to implicate
linkage to chromosomal segments of 10–20 megabases in an unbiased manner. Microsatellites,
also known as short tandem repeats (Weber and May 1989, Litt and Luty 1989), have
traditionally been utilized as markers. However, the use of single nucleotide polymorphisms
(SNPs) has gained popularity along with the HapMap project and the development of commercial
microarrays, “SNPchips” (Kruglyak 1997). SNPs consist of biallelic base-pair substitutions
occuring randomly in the genome, and are the most common forms of genetic polymorphisms.
Launched originally in October 2002, the HapMap project has now a goal of increasing the
density of SNPs across the genome from the average of 1/3,000 bases to about 1/600 bases.
The first genome-wide screen for asthma susceptibility loci was published in 1996
(Daniels et al. 1996). Since then, at least 17 additional genome-wide surveys have been carried
out in a variety of populations and suggested more than 30 different genomic regions for linkage
to asthma related traits (Ferreira et al. 2005) (Table 1). However, many studies lack proper
replication of the initial findings. Although small sample populations may explain some of the
false positive results, the study designs in most genome-wide scans are more likely to lead into
false negative findings because of the relatively wide gaps between the markers. Nevertheless,
there are several regions that have consistently shown a significant linkage in more than a few
studies and are likely to represent true asthma or atopy susceptibility loci (Wills-Karp and Ewart
2004).
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Table 1. Summary of results from genome-wide scans of asthma or related traits. Modified from Wills
Karp and Ewart 2004 and Ferreira et.al 2005. The most significant primary linkage regions are 2q14-q32
(containing e.g. cytotoxic T-lymphocyte associated protein 4 and IL-1 receptor antagonist), 5q31-q33 (Th2
type cytokine gene cluster including IL-4, IL-13, CD14 and b-adrenergic receptor (b-AR)); 6p24-p21
(human leukocyte antigen DRB1 (HLA-DRB1), tumor necrosis factor a); 7p15-p14; 11q13-q21 (near the B
chain of the high affinity receptor for IgE); 12q21-q24 (stem cell factor, interferon-?, signal transducer and
activator of transcription-6); 13q12-q14; and 20p13.
Population Study design:
Number of
families
(study
subjects;
markers)
Phenotypes Chromosomal
regions reported
References
Australian,
British*
80 (364; 296)
77
Asthma, atopy, total IgE,
SPT, blood eosinophils,
BHR
4q‡, 6‡, 7, 11q‡, 13q‡,
16‡
Daniels et al. 1996
African-
American,
Caucasian,
Hispanic
43–115
45–138
18–34
(1931; 323)
Asthma, atopy (SPT),
total IgE, Der-p-specific
IgE, asthma and
environmental tobacco
smoke exposure, Der p
and Der f mite reactivity
1p32, 1q, 2q21-23‡,
2q33‡, 3, 5q23-31‡, 5p15,
6p21.3-23‡, 8p23-21,
8p32, 9q,11p15, 11q21‡,
12q14-24.2‡, 13q21.3
qter‡, 14q11.2-13, 14q32,
15q13, 17p11.1-q11.2, 18,
19q13‡, 20p, 21q21
Xu et al. 2001a,
Mathias et al. 2001
Blumenthal et al.
2004a, b
German 97 (415, 156 sib
pairs; 351)
Asthma, total IgE,
specific IgE
2‡, 6‡, 9, 12‡ Wjst et al. 1999
Hutterites (a
founder
population of
European
descent)
1 (361-693; 563)
1 (292–324;
563)*
Asthma, BHR, SPT 1, 3p24.2-22, 5q23-31‡,
6‡, 12q15-24.1‡,16‡,
19q13‡, 21q21
Ober et al. 1998,
1999, 2000
Japanese 47 (197, 65
affected sib
pairs; 398)
Mite-sensitive atopic
asthma
4q35‡, 6p22-21.3‡, 5q31-
33‡, 12q21-23‡, 13q11‡,
13q14‡
Yokouchi et al.
2000
Japanese 48 (188, 67
affected sib
pairs; 400)
Total IgE, orchard grass -
specific IgE, orchard
grass -sensitive allergic
rhinitis
1p36.2, 3p24.1, 4p16.1‡,
4q13.3‡, 5q33.1‡, 9q34.3,
11q14.3‡, 12p13.1‡,
12q24.2‡, 16p12.3‡
Yokouchi et al.
2002
French 107 (493; 254) Asthma, total IgE, BHR,
SPT, blood eosinophils,
age of onset
1p31, 7q, 11p13, 11q13‡,
12q24‡, 13q31‡, 17q12-
21, 19q13‡
Dizier et al. 2000
Finnish
French-
Canadian*
86 (443; 312)
22
Asthma, total IgE, asthma
and high IgE
7p14-15§, 4q Laitinen et al. 2001
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Chinese 533 (2551; 422) Total IgE, specific IgE,
FEV1, FVC, BHR, blood
eosinophils, SPT
1, 2‡§, 4‡, 10, 16‡, 19‡,
22
Xu et al. 2001b
Dutch 200 (1174; 366) Total IgE, Der-p and
aeroallergen -specific IgE,
SPT, SPT to house dust
mite, blood eosinophils
2q‡, 6p‡, 7q, 11q‡, 13q‡,
17q, 22q
Koppelman
et al. 2002
Danish 48 (206; 446) Atopy, allergic asthma,
total IgE
1p36, 3q21-22, 5q31‡,
6p24-22‡
Haagerup et al.
2002
Caucasian 460 (920; 387) Asthma, asthma and
BHR, asthma and total or
specific IgE
20p13§ Van Eerdewegh et
al. 2002
Icelandic 175 (1134; 976) Asthma 14q24§ Hakonarson et al.
2002
French 295 (1,317; 396) Asthma, total IgE, SPT,
SPTQ, specific-IgE),
eosinophils, BHR, FEV1
12p13, 12q24 Bouzigon et al.
2004
Australian 539 (2,360; 396)  Eosinophil count 2q33, 8q24 Evans et al. 2004
European 82 (366; 603) Asthma, mite-sensitive
atopic asthma
2p12, 3q21, 16q21 Kurz et al. 2005
Australian 202 (591) SPT to house dust mite,
atopy BHR, FEV1, FVC,
asthma
20q13, 12q24 Ferreira et al. 2005
Caucasian 364 (1551; 396) Asthma, atopic asthma,
BHR
2p, 4p Pillai et al. 2006
*Replication study
‡Linkages identified in four or more studies
§Chromosomal regions providing significant evidence for linkage (many chromosomal regions
reported in the literature did not provide significant evidence for linkage).
BHR, bronchial hyperresponsiveness to methacholine challenge; FEV1, forced expiratory volume
in the first second; FVC, forced vital capacity; IgE, immunoglobulin E; SPT, skin prick test. SPT
(positive skin prick test response to at least one of 11 allergens), SPTQ score being the number of
positive skin test responses to 11 allergens and % predicted FEV.
2.2 Association studies
The hypothesis-dependent approach selects candidate genes that might have relevance in the
disease process (biological candidates) or of candidate-gene regions previously linked to the trait
of interest (positional candidates). The study designs can be either family- or population-based
(Risch 2000, Cardon et al. 2001). The population-based case-control studies are utilized in
studying the probabilities whether a specific genetic variant is overrepresented (or
underrepresented) in affected cases in comparison to non-affected controls. Haplotypes are
defined as a linear set of genetic markers on one chromosome that are inherited together
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(haplotype block) (Gabriel et al. 2002). By obtaining knowledge from several polymorphisms,
the misleading results often received by genotyping single polymorphisms can be avoided.
However, the controls and cases have to be carefully matched for age, sex and origin in order to
reduce genetic heterogeneity. These problems can be overcome with family-based settings, where
transmission disequilibrium tests (TDTs) are utilized in comparing the transmissions and non-
transmissions of the marker allele from heterozygous parents to the affected offspring (Spielman
and Ewens 1996).
The  current  tools  for  biocomputing  allow  researchers  to  relatively  easily  dissect  the
disease-associated polymorphisms to exceed the statistical treshold. However, a possibility of
false positive results remains with each test performed. This can be corrected for multiple testing,
where the probability of false positive results is simulated by repeated analysis of randomly
selected samples within the study population (permutation test).
Regarding asthma, more than 150 genetic linkage studies have suggested a variety of
candidate genes in 500 loci (Wills-Karp and Ewart 2004). A recent review reported 118 genes
associated with an asthma- or atopy-related phenotype, 54 genes that were replicated in 2-5
independent samples, 15 genes in 6-10 independent samples, and 10 genes in >10 independent
samples, reported in a total of 492 articles (Ober and Hoffjan 2006). Genome-wide screening
studies have provided novel candidate loci with potential susceptibility genes, which often show
important immune-responses. In particular, variation in ten genes has been associated with
asthma-related phenotypes in ten or more studies. These genes are IL-4 and IL-4RA, IL13, b-AR,
tumor necrosis factor, HLA-DRB1 and the B-subunit of the high-affinity IgE receptor, as well as
CD14, HLA-DQB1, and a disintegrin and a metalloproteinase 33 (ADAM33) genes.
2.3 Positional cloning
In positional cloning, the susceptibility loci revealed after genome-wide searches are narrowed
down by genetic association analysis using genetic markers at higher density in order to identify
the genes responsible for the linkage. Finally, expression pattern analysis and further functional
characterization of the gene and its variants are warranted to indicate proper causality. Only
recently, a few groups have progressed from broad linkages to identification of the susceptibility
gene (Kere and Laitinen 2004). This has led to the discovery of novel signaling pathways
transmitted by susceptibility genes such as ADAM33 and GPRA.
2.3.1 ADAM33
ADAM33 was the first asthma susceptibility gene identified by positional cloning. In the original
report published in 2002, linkage to asthma was studied in 362 and 98 Caucasian families with
asthmatic sibling pairs in the United Kingdom and United States, respectively (Van Eerdewegh et
al. 2002). Followed by a microsatellite marker genome scan, a linkage region of about 2.5
megabases containing 40 genes was discovered on chromosome 20p13. Case-control studies
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carried out with 135 SNPs showed that 14 SNPs localized to the ADAM33 gene region. TDT and
haplotype analyses of five ADAM33 SNPs supported an association with asthma and BHR.
ADAM33 belongs to a family of zinc-dependent membrane-anchored metalloproteinases
that also have effects on cell adhesion and intracellular signalling. It is selectively expressed in
mesenchymal  cells  (airway  SMC  and  fibroblasts)  (Van  Eerdewegh  et  al.  2002),  but  not  in  the
immune or inflammatory cells (Umland 2003, Haitchi 2005). Thus, it could play a role in
predisposing to the reduced lung function characteristic of asthma, possibly by influencing
airway wall remodelling.
The over ten replication studies of ADAM33 and asthma have yielded somewhat
conflicting results, although the results have been confirmed in African American, Hispanic and
US Caucasian outbred populations, as well as in Dutch (Howard et al. 2003), German (Werner et
al. 2004), Korean (Lee et  al. 2004) and Japanese (Noguchi et al. 2006) populations. However,
also negative association studies exist (Lind et al. 2003). A recent meta-analysis combining the
results of positive and negative studies from eight populations yielded a maximum odds ratio of
1.46 (p=0.0001) for a common ADAM33 SNP called ST+7 (risk allele frequency 84.9% in
asthmatics and 79.1% in controls) (Blakey et al. 2005). In this method, the chromosomes are
divided into bins of defined length, and categorized according to their linkage scores (Wise et al.
1999). As observed in many association studies, the risk effects are smaller than in the original
report (the odds ratio in the most significantly associated SNP was 1.95 in the original study).
2.3.2 DPP10
Dipeptidyl peptidase 10 (DPP10) was discovered by refining the linkage peak on chromosome
2q14-q32 (Allen et al. 2003). An association study revealed a 460-kb genomic region with high
linkage disequilibrium. The authors located the first, alternatively spliced exons belonging to a
large gene spanning over 1 Mb of genomic DNA and completed the gene sequence with three
rounds  of  rapid  amplification  of  cDNA ends  (RACE)  -PCR.  The  gene, DPP10 (also  known as
DRP3 and DPPY), encoded a transmembrane protein with a small intracellular amino terminus
and a large extracellular domain (Engel et al. 2003, Hiramatsu et al. 2003, Ludwig et al. 2003,
Rasmussen et al. 2003). DPP10 was suggested to act as a peptidase on the two terminal peptides
of cytokines and chemokines such as IL-2, RANTES and eotaxin (Allen et al 2003), although the
enzymatic region has been previously presumed non-functional (Wada et al. 1992, Kin et al.
2001, Qi et al. 2003). Because there were no coding polymorphisms in the DPP10 gene, the
influence of the associated locus was proposed to derive from indirect actions of the adjacent
CdxA promoter on DPP-10 expression. Initial functional evaluation of this hypothesis
demonstrated that the CdxA promoter was capable of differentially binding to nuclear protein
extracts in a manner dependent on the present allele (Allen et al. 2003).
DPP10 is prominently expressed in the brain and additionally in pancreas, adrenal glands
and trachea (Allen et al. 2003, Qi et al. 2003). Recently, DPP10 has been found to modulate the
properties of Kv4.2 channels that are responsible for rapidly inactivating outward K+ current in
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many neuroendocrine cells (Zagha et al. 2005, Ren et al. 2005). This suggests that DPP10 may
have additional functions in regulating airway smooth muscle tone.
Consistent with the original report, independent mouse genome screens have linked AHR
in  mice  to  a region homologous to the location of DPP10 in humans (De Sanctis et al. 1995,
Ewart et al. 2000), but thus far, there are no replication studies among humans.
2.3.3 PHF11
One of the most replicated segments in asthma genetics is the chromosomal region 13q14
(Daniels et al. 1996, Hizawa et al. 1998, Kimura et al. 1999 and Beyer et al. 2000). The gene
named plant homeodomain finger protein 11 (PHF11 alias renal carcinoma autoantigen) was
identified in a similar approach to DPP10. In the linkage region, Zhang and co-workers assessed
linkage disequilibrium patterns around a single significantly associated marker using SNPs
between  brief  gaps  (Zhang  et  al.  2003).  Concurrently,  they  studied  the  gene  content  of  the
segment and found strongest associations of SNP markers to a 100-kb high linkage
disequilibrium interval containing the gene for PHF11. The gene product contains two zinc
fingers suggesting involvement in chromatin remodelling or transcriptional regulation. The close
proximity of the PHF11 gene  to a protein complex containing a histone methyl transferase
SETDB2 suggests that the two genes might be co-ordinately expressed or that a combined
product might be expressed. Both PHF11 and SETDB2 proteins are expressed in B lymphocytes.
PHF11 contains several splice variants, which were overexpressed in activated peripheral blood
lymphocytes (Zhang et al. 2003). The interactions and genetic mechanisms underlining the
associations are complex. Thus far, there are no replication studies for asthma, but two
polymorphisms in the PHF11 gene were associated with childhood atopic dermatitis in
Australian population (Jang et al. 2005).
2.3.4 CYFIP2
Noguchi and coworkers constructed a saturation map using 27 microsatellite markers around the
9.4-Mb linkage region that had previously shown linkage to atopic asthma (Yokuchi et al. 2000)
and other asthma-related phenotypes on chromosome 5q33 (Ober et al. 1998). The authors
performed mutation screening and association analyses  of  26  genes  that  existed  between  the
markers (Noguchi et al. 2005). Transmission disequilibrium test analysis of altogether 105
polymorphisms in 155 Japanese families with asthma revealed strong association between asthma
and polymorphisms in cytoplasmic fragile X mental retardation protein -interacting protein 2
gene  (CYFIP2). Six polymorphisms in CYFIP2 were in complete linkage disequilibrium and
associated significantly with the development of asthma (odds ratio 5.9). In real-time quantitative
PCR analysis, subjects homozygous for the haplotype overrepresented in asthmatics showed
significantly increased levels of CYFIP2 expression in lymphocytes when compared with the
subjects heterozygous for the haplotype.
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Interestingly, CYFIP2 protein expression was increased in CD4+ and CD8+ T cells from
multiple sclerosis (MS) patients when compared with the cells from healthy controls or patients
with inflammatory bowel disorder (IBD) (Mayne et al. 2004). Several findings suggested that
overexpression of CYFIP2 facilitates increased T cell adhesion properties.
2.3.5 HLA-G
Linkage of asthma and related phenotypes to chromosome 6p21 has been reported in seven
genome scans making it the most replicated susceptibility loci for asthma (Table 1). Nicolae and
coworkers conducted a genome-wide screen of families who participated in the Collaborative
Study on the Genetics of Asthma (CSGA 1997, Xu et al. 2001a, Nicolae et al. 2005). They
focused on 35 white families and 46 white child-parent trios with best associations with asthma.
The linkage region contained 20 genes and at least 30 pseudogenes spanning 1 Mb of
genomic DNA. Additional 59 polymorphisms between 10–20-kb intervals in 19 genes, two
pseudogenes, and the intergenic regions flanking the HLA-A and HLA-G loci were genotyped.
Five linkage disequilibrium blocks were identified and variation in the HLA-G gene accounted
for  most  of  the  linkage  as  confirmed  by  TDT.  The  results  were  replicated  in  two  distinct
populations, although the gene variants differed between populations. In both Hutterites (a
founder population of European descent) and Dutch families, significant association of HLA-G
with BHR was observed (Ober et al. 2000, Koppelman et al. 2002).
HLA-G undergoes alternative splicing events providing either membrane-bound or
soluble proteins. In addition to its antigen presenting properties, HLA-G may have
immunosuppressive properties e.g. in acute and chronic organ rejection (Lila et al. 2000). HLA-G
is expressed in pulmonary macrophages and dendritic cells (Pangault et al. 2002) and its
expression has also been linked to ulcerative colitis (Torres et al. 2004), psoriasis (Aractingi et al.
2001) and MS (Mitsdoerffer et al. 2005). HLA-G has unique tissue expression pattern in fetal
cells at the maternal–fetal interface indicating that it may be involved in the biological
mechanisms that protect the fetus during pregnancy (Hunt et al. 2005). In peripheral blood
monocytes, HLA-G is expressed as membrane-bound, but is secreted as soluble molecules upon
IL-10  activation.  Regarding  to  asthma,  LPS  stimulation  induced  the  secretion  of  IL-10  and
soluble HLA-G1/HLA-G5 molecules in healthy subjects, whereas the levels of IL-10 and
detectable soluble HLA-G molecules were reduced in asthma patients (Rizzo et al. 2005). Thus,
the loss of immunosuppressive effects of HLA-G could contribute to the persistence of airway
inflammation in asthma.
2.3.5 GPRA
Genome-wide scan in 86 pedigrees recruited from a founder population in Kainuu province
revealed  one  genomic  region  that  showed  significant  linkage  to  asthma-related  traits  on
chromosome 7p (Laitinen et al. 2001). Further evaluation of the statistical significance of the
finding was performed with simulations. The permutation tests showed that linkage peak
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exceeded the genome-wide significance level and was highly unlikely a false positive finding.
The results were then further confirmed in two independent data-sets: French-Canadians and
North-Karelians. Interestingly, the 7p14 region had exceeded the threshold levels in an Australian
sib study to detect linkage to allergic asthma (Daniels et al. 1996). In an attempt to identify the
effective  gene,  an  association  study  for  a  potential  candidate  gene  encoding  the g-chain of the
heterodimeric g/d T cell receptor on the linkage region showed, however, no evidence of
associated polymorphisms (Polvi et al. 2002).
The further finemapping of the associated region led to the discovery of two novel genes:
GPRA and AAA1. As the genes were identified in the first publication of this thesis, the positional
cloning and the characterization of the genes will be described in the results section in more
detail. Similarly, the results of the replication studies will be enlightened in the discussion part.
Identification of a novel GPCR rapidly received a lot of attention. Research carried out in
other groups led to the discovery of a novel linear 20 residue peptide that activated GPRA via
both Gaq and Gas pathways resulting in intracellular Ca2+ mobilization as well as protein kinase
C and A activation (Mori et al. 2003, Gupte et al. 2004, Xu et al. 2004). The polypeptide might
derive from an uncharacterized precursor, mapping in humans to chromosome 10q26, which is
phylogenetically conserved across mammals. The precursor protein contains the typical structural
features of a neuropeptide precursor. A hydrophobic signal peptide immediately follows the
initiation  of  translation  (AUG),  and  the  immature  peptide  is  preceded  by  a  pair  of  basic  amino
acids (Lys-Arg) that are presumed processing sites for proteolytic cleavage. Because of the amino
terminal serine, this molecule and its cognate receptor were termed neuropeptide S (NPS) and
neuropeptide S receptor (NPSR), respectively (Xu et al. 2004). The primary structure of NPS is
highly conserved among vertebrates, but the gene is absent in fish (zebrafish or fugu), amphibian,
and reptile DNA sequences indicating that this transmitter peptide may have occurred quite late
during vertebrate evolution. The residues 1-10 of human NPS are sufficient for mimicking the
effect of the complete peptide (Roth et al. 2006). The peptide may contain several domains: The
domain containing the residues Phe2, Arg3, and Asn4 crucial for biological activity is separated
by a hinge region Val6-Gly7 from the sequence Thr8-Gly9-Met10 required for receptor
activation (Roth et al. 2006).
3. G PROTEIN-COUPLED RECEPTORS IN ASTHMA
A variety of important effector molecules in asthma mediate their effects on target cells through
GPCRs, which contribute to both the development and the maintenance of allergic processes. In
airway smooth muscle, signaling through GPCRs mediates numerous functions including
contraction, growth and functions that orchestrate airway inflammation and promote remodeling
of the airway wall. Mediators of allergic inflammation that trigger cyclic adenosine
monophosphate (cAMP) -associated GPCRs might play a role in peripheral tolerance
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mechanisms against allergens. Current strategies for drug development and allergen-specific
immunotherapy exploit these observations.
GPCRs are the most prominent targets for drug discovery and according to estimations,
up to half of all modern drugs are targeted at GPCRs (Gudermann et al. 1995, Flower 1999). In
addition, several ligands for GPCRs are found in the top-100 selling pharmaceutical products.
200-500 orphan GPCRs may still exist in the human genome providing many opportunities for
drug discovery (Howard et al. 2001). Pharmacological agents that block or stimulate GPCR
action are commonly utilized in the treatment of allergic diseases.
3.1 The GPCR superfamily: classification
The superfamily of GPCRs is evolutionary highly conserved and one of the largest groups of
proteins in animals (Lander et al. 2001, Venter et al. 2001). The structural characteristics of
GPCRs show a topology of seven transmembrane (TM) a-helices connected by three intracellular
loops and three extracellular loops (Baldwin et al. 1993). The human genome contains more than
800 genes for GPCRs, which may represent up to 2-3 % of all protein coding genes (Fredriksson
et al. 2003). GPCRs play important roles both in the major peripheral organ systems and in the
central nervous system. The receptors can be classified by several ways based e.g. on their amino
acid similarities (Vassilatis et al. 2003), ligand binding sites, receptor function and ligand
structure (Bockaert and Pin 1999) as well as homology in the human genome (Fredriksson et al.
2003).
According to the phylogenetic analysis of GPCRs in the human genome, the receptors can
be divided into five main families, Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and
Secretin (Fredriksson et al. 2003). Rhodopsin, Secretin and Glutamate families correspond to A,
B and C clans in the traditional A-F classification of GPCRs, respectively, where the subclans are
defined using roman number nomenclature (Attwood and Findley 1994, Kolakowski 1994). The
A-F classification covers all GPCRs in both vertebrates and invertebrates, and some families of
the system do not exist in humans.
The Rhodopsin family is by far the largest of the five human GPCR families and most of
the current drug targets among GPCRs are found within this family, which contains 15, 241, 24,
24 and 15 non-olfactory receptors, respectively (Attwood and Findley 1994). The rhodopsin
family has several characteristics such as the Asn-Ser-x-x-Asn-Pro-x-x-Tyr motif in TMVII, the
Asp-Arg-Tyr (DRY) motif or the Asp(Glu)-Arg-Tyr(Phe) sequence at the border between TMIII
and the second intracellular loop. The ligands for most of the rhodopsin family receptors bind
within a cavity between the TM regions (Baldwin et al. 1993) except for the glycoprotein binding
receptors such as luteinizing hormone, follicle stimulating hormone and thyroid-stimulating
hormone receptors, where the ligand-binding domain is in the amino terminus. In addition to
hormones, rhodopsin family GPCRs can be activated by biogenic amines, peptides, nucleosides
and nucleotides as well as lipids and eicosanoids. The large group of olfactory receptors belongs
to this family but two thirds of the 900 genes in the subgroup represent pseudogenes in humans.
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Most of the olfactory receptors are orphans with unknown ligands (Lane et al. 2002). The
rhodopsin family can be further subdivided into four evolutionary collectively inherited receptor
groups (Fredriksson et al. 2003). The receptors with bold font are presented in more detail in
further chapters.
I) The a-group of rhodopsin family receptors consists of five main branches including the
prostaglandin, amine, opsin, melatonin, and MECA receptor clusters (including receptors
for melanocortin, endothelial differentiation, cannabinoids and adenosine). Especially, the
prostaglandin and amine receptor clusters are of importance in the disease mechanisms of
asthma. The former includes receptors for eicosanoids such as various prostaglandins and
thromboxane A2, whereas the latter includes receptors for serotonin, dopamine, and
histamine as well as muscarinic and adrenergic receptors. All the known ligands for the
amine receptor cluster are structurally related small amine molecules with a single aromatic
ring.
II) The b-group includes several neuropeptide receptors such as the neuropeptides FF and Y
receptors, but also endothelin-related receptors, arginine-vasopressin receptors and oxytocin
receptor. This group of receptors has no branches and it consists of receptors with peptides
as ligands. GPRA belongs to this group of receptors.
III) The g-group has three main branches: the SOG receptor cluster (including somatostatin and
opioid receptors), melanin-concentrating hormone (MCH) receptor cluster, and the
chemokine receptor cluster. In addition to the classical chemokines, known ligands of the
last cluster include complement component 5a.
IV) The d-group has four main branches: MAS1-related receptor cluster, glycoprotein receptor
cluster, purin receptor cluster, and olfactory receptor cluster. The known ligands for the
purin receptor cluster include extracellular nucleotides, leukotrienes and thrombin. The
nucleotide-binding and related receptors have the most diffuse topology within this group.
These receptors include the formyl peptide binding receptors, thrombin receptors and
cysteinyl leukotriene receptors (CysLTRs).
3.2 G protein-coupled signal transduction
GPCRs primarily elicit responses to external stimuli by coupling to heterotrimeric G proteins
(guanine nucleotide-binding proteins), which transduce signals to various intracellular effectors
(Figure 1). G proteins are composed of a guanine nucleotide-binding a subunit and a high-
affinity dimer consisting of b and g subunits. In the inactive state, the G protein exists as a trimer
of the guanosine diphosphate (GDP) -bound a-subunit and the bg -complex associated together.
Stimulation (e.g. ligand binding) induces a conformational change in the receptor, which
activates the heterotrimeric G protein to exchange GDP to guanosine triphosphate (GTP). This in
turn leads to the dissociation of the a-subunit from the bg -complex, which modulate the
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downstream effectors of the signaling cascades. The a-subunit possesses very low intrinsic
GTPase activity, which hydrolyses GTP back to GDP and Pi terminating G protein activation.
The inactive a-subunit is able to reassociate with the bg dimer (Neves et al. 2002).
Ga subunits are classified into four subfamilies based on their amino acid sequences and
function:  the  Gi,  Gq,  Gs  and  G12 subfamilies  (Neves  et  al.  2002).  The  type  of  the  Ga subunit
determines the specific signaling pathways that are turned on upon receptor activation. Briefly,
Gs proteins activate adenylyl cyclase to stimulate the production of cAMP; Gq proteins activate
phospholipase C? to produce diacylglycerol and inositol 1,4,5-trisphosphate, which facilitates the
controlled release of Ca2+ from intracellular  stores  (Smrcka  et  al.  1991,  Taylor  et  al.  1991).  Gi
proteins inhibit adenylyl cyclase, regulate ion channels, and activate some isoforms of
phospholipase C? via the G?? subunits. G12 proteins activate, for example, the Rho guanine
nucleotide exchange factor p115 Rho GEF, which controls cell motility (Hart et al. 1998).
Figure 1. G protein-coupled signaling pathways. Abbreviations: cAMP, cyclic adenosine monophoshate;
DAG, diacyl glycerol; GDP/GTP, guanosine di/triphosphate; PLC, phopholipase C; PKC, protein kinase C;
Rho GEF, Rho guanine nucleotide exchange factor
In  addition,  the  downstream effector  molecules  stimulated  via  G protein  activation  may
include guanylyl cyclases, phosphodiesterases, phospholipase A2, and phosphoinositide 3-
kinases, which activate or inhibit second messengers cyclic guanosine monophosphate,
phosphatidyl inositol (3,4,5)-triphosphate, arachidonic acid and phosphatidic acid, respectively
(Marinissen and Gutkind 2001, Kozasa 2001, Offermanns 2003).
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3.3. GPCRs associated with asthma susceptibility
Genetic variations in several GPCRs associate with asthma susceptibility and some of them are
reviewed below. Although b2-adrenoreceptors (b-ARs) may not be causally involved in the
pathophysiology of asthma, they are important therapeutic targets for symptoms of asthma. The
positional cloning of DPP10 (section 2.3.2) and the association of chemokines and their receptors
with asthma emphasize the role of adaptive immunity and leukocyte activation in the disease
mechanisms. On the other hand, the importance of crosstalk between innate and adaptive
immunity is underlined with genetic studies demonstrating associations with the complement
system and asthma. In addition, recent experimental and genetic studies have highlighted the role
of effector molecules such as arachidonic acid metabolites (prostaglandins, thromboxanes and
leukotrienes) and their GPCRs in the pathogenesis of allergic inflammation and asthma. The
complex etiology of aspirin-induced asthma observed in up to 10 % of asthmatic patients points
towards an abnormality of arachidonic acid metabolism (Figure 2) and overexpression of
cysteinyl leukotrienes.
Figure 2. Prostaglandin H2 is the precursor of
many prostaglandins and thromboxanes, which
are formed by the phospholipase A pathway in a
process involving free arachidonic acid release.
The cyclooxygenase (COX) enzymes are
needed for the further synthesis of
prostaglandins and thromboxane A2.
Leukotrienes are synthesized by a distinct
lipoxygenase pathway, which cannot be inhibited
by aspirin. LTC4 is the parent compound of the
cysteinyl leukotrienes (LTs) including LTD4 and
LTE4. Arachidonic acid metabolites participate
both into early and late phases in allergic
responses. Modified from Cabral et al. 2005.
3.3.1 Prostaglandin, leukotriene and thromboxane receptors
Prostaglandin (PG) D2 mediates its effects via two receptors, D prostanoid (DP) 1 and 2, which
differ in their ligand binding affinities and expression patterns. DP1, although not expressed by T
cells, mediates PGD2-directed T-cell trafficking through the induction of chemokine expression
(Hirai et al. 2001). In mice lacking the prostanoid DP1 receptor (DP1-/- mice), the concentrations
of the Th2 cytokines and the extent of lymphocyte accumulation in the lung of OVA-challenged
DP1-/- mice were reduced when compared with the wild-type controls. Furthermore, DP1-/- mice
showed only marginal infiltration of eosinophils into the lung and failed to develop BHR upon
OVA challenge (Matsuoka et al. 2000). DP2 receptor was originally termed as chemoattractant
receptor-homologous molecule expressed on Th2 (CRTH2) cells and it is a member of the
chemoattractant receptor subgroup (Abe et al. 1999, Nagata et al. 1999).
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Previous linkage studies have shown that the human genome region 14q22.1 associates
with asthma. An intronic SNP in the DP1 gene is preferentially transmitted to asthmatic children
(Noguchi et al. 2002). In 2004, Oguma and co-authors identified four novel and two previously
reported SNPs on 14q22.1 in DP1 and its vicinity, which significantly associated with asthma in
both white and black populations (Oguma et al. 2004). The polymorphisms in the promoter
region of the gene were underrepresented in asthmatic patients and led to a reduced mRNA
transcription and lower levels of receptor protein. In asthma, PGD2 production is activated in
mast cells and monocytes/macrophages. PGD2-mediated events include vasodilatation and
increased capillary permeability, leading to oedema formation, increased mucus production,
bronchoconstriction and eosinophil, basophil and Th2 cell recruitment (Hirai et al. 2001). Thus,
the reduced receptor levels in control population lead to an overall asthma-protective effect.
Similar associations have been detected with CysLTRs. The cysteinyl leukotrienes are
peptide-conjugated bioactive lipids that are prominent products of immunologically activated
eosinophils, basophils, mast cells and macrophages recognized as potent mediators of
bronchoconstriction (Dahlén et al. 1980, Kanaoka and Boyce 2004). In addition, they are potent
inflammatory mediators that initiate and propagate a diverse array of biologic responses such as
increase microvascular permeability, stimulate mucus secretion, decrease mucociliary clearance
and recruit eosinophils into airways (Holgate et al. 2003).  These effects are mediated through
activation of at least two receptors, CysLTR1 and CysLTR2 expressed on bronchial smooth
muscle (Lynch 1999 and Heise 2000), pulmonary interstitial macrophages, mast cells (Mellor et
al. 2001) and peripheral blood leukocytes (Figueroa et al. 2001). For CysLTR1, the order of
ligand potency is ranked as LTD4 > LTC4 > LTE4. The CysLTR1-specific antagonists, such as
montelukast, zafirlukast and pranlukast, are currently used to control bronchoconstriction and
inflammation in asthmatic patients. However, the individual responses are highly variable. In
fact, approximately 30% of the asthmatics do not respond to the treatment (Bleecker et al. 2000,
Asano et al. 2002), although montelukast significantly reduced the airway remodelling events in a
mouse model of asthma (Jones et al. 1995, Henderson et al. 2002). For CysLTR2, the rank order
of potency has been reported as LTC4 = LTD4 > LTE4 (Heise et al. 2000, Nothacker et al. 2000,
Takasaki et al. 2000). CysLTR2 maps to 13q14 near a linkage region for atopic asthma. In a
recent study, a coding polymorphism in the CysLTR2 was associated with asthma in two family-
based collections from Denmark and the United States. The polymorphism resulted in reduced
receptor affinity to LTD4 providing an asthma-protective effect (Pillai et al. 2004).
Thromboxane A2 (TXA2) actions are mediated through a G protein-coupled TBXA2R
receptor (Coleman 1994). The two isoforms, named TPa and TPb, share the first 328 amino acids
but have differences in the length of their carboxy-terminal tails. TBXA2R is located on
chromosome 19p13.3 and is composed of 343 amino acids. Significantly, a synonymous
polymorphism in the TBXA2R gene has been found to associate with asthma related traits in
Japanese, Chinese and Korean populations (Unoki et al. 2000, Leung et al. 2002, Shin et al. 2003,
Hong et al. 2005, Kim et al. 2005). The polymorphism may regulate TBXA2R gene expression at
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transcriptional or translational level, but the mechanisms are yet unclear. In addition to inducing
platelet aggregation, TXA2 has potent bronchoconstricting activity (Nagai et al. 1993, Francis et
al. 1991). Therefore TXA2 and its receptors play a role in AHR and are plausible candidate genes
in the pathogenesis of asthma (Fujimura et al. 1991, Nagai et al. 1993).
3.3.2 Chemokine receptors
Chemokines are divided into four subclasses distinguished on the basis of the arrangement of the
amino terminal cysteine residues (Zlotnik and Yoshie 2000): CXC chemokines (CXC ligands,
CXCL), CC chemokines (CCL), C chemokines (XCL), and CXXXC chemokines (CX3CL).
Chemokines mediate their effect via GPCRs. Up to now, at least 10 CC chemokine receptors
(CCRs) and six CXC chemokine receptors (CXCRs) comply with the criteria of the chemokine
nomenclature (Elsner et al. 2004) (Table 2).
Of the various chemokine receptors, especially CCR3, also known as the eotaxin receptor
appears to play a major role in allergic diseases (Bisset and Schmid-Grendelmeier 2005). The
receptor has several ligands as chemoattractants (Table 2) and polymorphisms in the CCL11
(Eotaxin-1) and CCL24 (Eotaxin-2) genes associate with asthma-related traits (Shin et al. 2003,
Chang et al. 2005). CCR3 is expressed constitutively on the surface of eosinophils, where the
receptor is the dominant chemokine receptor (Ponath et al. 1996). In CCR3-deficient mice,
eosinophils are unable to extravasate through the vessel wall (Humbles et al. 2002). Also other
cell types including Th2 cells express CCR3 constitutively or upon cytokine activation (Sallusto
et al. 1997, Uguccioni et al. 1997, Ochi et al. 1999). In mast cells, CCR3 can be stored in
secretory granules and is mobilized towards the cell surface following activation mediated by
Fc?RI for IgE (Price et al. 2003). The binding of CCL11 ligand to the newly exposed CCR3 is
able to provide a second signal, leading to amplification of Fc-receptor for IgE-dependent IL-13
production.
Interestingly,  CCL11  acts  as  an  antagonist  to  CXCR3,  the  gene  of  which  is  located  on
chromosome Xq13 and associates with asthma and atopy especially in atopic male subjects
(Cheong et al. 2005). CCL11 is also another ligand for CCR5. A 32-bp deletion in the CCR5
gene, initially linked with low human immunodeficiency virus 1 prevalence (Samson 1996),
associates with reduced prevalence of asthma in several studies (Hall et al. 1999, Mitchell et al.
2000, McGinnis et al. 2002), especially during childhood (Srivastava et al. 2003). The CCR5
gene with the deletion is in close proximity on the 3p21 chromosome to CCR1, CCR2, and
CCR3. Thus, the linkage disequilibrium does not exclude an association between these other
genes and asthma. Indeed, a silent polymorphism in the CCR3 gene showed significant
association with asthma in Japanese but not in British population (Fukunaga et al. 2001).
However, no replication studies exist so far.
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Table 2. CC and CXC chemokine receptors: Cellular distribution and ligands. Modified from Elsner and
coauthors 2004.
Receptor Cellular distribution Ligand
CCR1 Monocyte, macrophage, dendritic
cell, T cell, B cell, eosinophil,
basophil, neutrophil
CCL2 (MCP-1), CCL3 (MIP-1?), CCL5 (RANTES),
CCL7 (MCP-3),CCL8 (MCP-2), CCL14 (HCC-1),
CCL15 (HCC-2), CCL16 (HCC-4), CCL23 (MPIF-1)
CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2),
CCL12, CCL13 (MCP-4), CCL16 (HCC-4)
CCR2 Monocyte, macrophage, immature
dendritic cell, natural killer cell,
basophil Antagonistic: CCL11 (Eotaxin), CCL26 (Eotaxin-3)
CCL5 (RANTES), CCL7 (MCP-3), CCL8 (MCP-2),
CCL11 (Eotaxin), CCL13 (MCP-4), CCL14 (HCC-1),
CCL15 (HCC-2), CCL24 (Eotaxin-2), CCL26
(Eotaxin-3), CCL28 (MEC)
CCR3 Eosinophil, basophil, mast cell, T cell
(Th2), keratinocyte
Antagonistic: CXCL9 (MIG), CXCL10 (IP-10),
CXCL11 (I-TAC), CCL18 (MIP-4/Ck?7/PARC)
CCR4 T cells (Th2), basophil, immature
dendritic cell
CCL17 (TARC), CCL22 (MDC)
CCR5 Monocyte, macrophage, dendritic
cell, natural killer cell, T cell (Th1),
thymocyte
CCL3 (MIP-1?), CCL4 (MIP-1ß), CCL5 (RANTES),
CCL8 (MCP-2), CCL11 (Eotaxin), CCL14, CCL16
(HCC-4), CCL26 (Eotaxin-3)
CCR6 Monocyte, macrophage, dendritic
cell, T cell, B cell
CCL20 (MIP-3?)
CCR7 Dendritic cell, T cell, B cell CCL19 (MIP-3?), CCL21 (SLC)
CCR8 Monocyte, T cell, B cell, neutrophil,
thymocyte
CCL1 (I-309), CCL4 (MIP-1?), CCL17 (TARC)
CCR9 T cell, thymocyte CCL25 (TECK)
CCR10 T cell, melanocyte, Langerhans cell CCL27 (CTACK), CCL28 (MEC)
CXCR1 Neutrophil, T cell, monocyte,
macrophage, dendritic cell
CXCL1 (GRO-?), CXCL6 (GCP-2), CXCL8 (IL-8)
CXCR2 Neutrophil, T cell, monocyte,
macrophage, dendritic cell
CXCL1 (GRO-?), CXCL2 (GRO-?), CXCL3 (GRO-
?), CXCL5 (ENA-78), CXCL6 (GCP-2), CXCL7
(NAP-2), CXCL8 (IL-8)
CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC)CXCR3 Neutrophil, T cell (Th1), B cell,
dendritic cell Antagonistic: CCL11 (Eotaxin)
CXCR4 Neutrophil, T cell, B cell, monocyte,
macrophage, dendritic cell,
eosinophil, natural killer cell (CD16)
CXCL12 (SDF-1?, -?)
CXCR5 T cell, B cell, monocyte, macrophage CXCL13 (BCA-1)
CXCR6 T cell, dendritic cell CXCL16
MIP, macrophage inflammatory protein; RANTES, regulated upon activation, normal T-cell expressed and secreted;
MCP, monocyte chemotactic protein; HCC, hemofiltrate CC chemokine; MPIF, myeloid progenitor inhibitory factor;
MEC, mucosae-associated epithelial chemokine; TARC, thymus and activation-regulated chemokine; MDC,
macrophage-derived chemokine; SLC, secondary lymphoid-tissue chemokine; TECK, thymus-expressed chemokine;
GCP-2, granulocyte chemotactic protein; NAP, neutrophil activating protein; ENA-78, epithelial neutrophil
activating protein; GRO, growth-related oncogene; IP-10, interferon-?-inducible protein; MIG, monokine induced by
INF-?; I-TAC, IFN-inducible T cell alpha chemoattractant; SDF, stromal cell-derived factor; BCA, B cell-attracting
chemokine; PARC, pulmonary and activation-regulated chemokine; Ck?7, chemokine ?7; CCL14 is HCC-1.
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The paradigm that Th1 cells preferentially express CXCR3 and CCR5 and Th2 cells
preferentially express CCR3, CCR4, and CCR8 has been well established in the settings of
polarized cell lines in vitro, although the situation appears more complicated in vivo
(D’Ambrosio et al. 1998, Sallusto et al. 1998). After extensive studies, small molecular inhibitors
for CCR2, CCR3, CCR4 and CCR8 are in the development for asthma. Because these chemokine
receptors are expressed on inflammatory cells in the circulation that respond to chemokines
released  locally  in  the  airways,  the  inhibitors  are  more  likely  to  be  useful  as  oral,  rather than
inhaled drugs (Barnes 2004).
3.3.3 Complement receptors
The complement  system consists  of  approximately  20  circulating  serum proteins.  Activation  of
the system links the innate and adaptive immunity through generating two protein anaphylatoxins
C3a and C5a, which mediate their effects on smooth muscle contraction, vascular permeability
and leukocyte chemotaxis through specific C3a and C5a receptors (Gerard and Gerard 1991,
Ames et al. 1996). In addition to C5aR, C5a binds with high affinity to another receptor C5L2,
which is not G protein-coupled (Ohno et al. 2000). Activation products of C3a and C5a play a
major role in phagocytosis and inflammation, but also in adaptive immunity. Foreign particles
taken up by the complement receptors and processed in antigen-presenting cells are presented to
T cells via major histocompatibility complex class II molecules. Thus, the complement receptors
play a dual regulatory role in C3a and C5a signaling by protecting against Th2-mediated immune
responses  at  the  beginning  of  the  immune  responses  and  a  proinflammatory  role  once  the
responses are established.
C3aR-deficient mice displayed enhanced susceptibility to LPS-challenge with
significantly enhanced mortality (Kildsgaard et al. 2000) and near complete protection from the
development of hyperresponsiveness to methacholine in the mouse model of asthma (Humbles et
al. 2000). C5aR expression was originally described on myeloid cells (Chenoweth and Hugli
1978, Gerard and Gerard 1991), but it is also expressed in endothelial and epithelial cells of many
organs, especially in the lung and liver (Haviland et al. 1995). A natural deletion in the coding
sequence of the C5 gene lead to C5-deficiency and increased susceptibility for allergen-induced
AHR in a mouse model of asthma (Karp et al. 2000).
Interestingly, several genome-wide scans for asthma susceptibility loci have intervals that
include C5 (chromosome 9q32-q34) and C5aR (chromosome 19q13.3-q13.4) as well as C3
(chromosome 19p13.2-p13.3) (CSGA 1997, Ober et al. 1998, Wjst et al. 1999, Blumenthal et al.
2004b). In 2004, Hasegawa and co-authors identified a high-risk haplotype of the C3 gene for
childhood and adult bronchial asthma and a low-risk haplotype for adult bronchial asthma in
Japanese population (Hasegawa et al. 2004). They also found that severity of childhood bronchial
asthma was associated with SNPs in the C3aR1 gene and a C5 haplotype was protective against
childhood and adult asthma. Variants of the C3 gene  were  also  associated  with  asthma  and
related phenotypes in African Caribbean families (Barnes et al. 2006).
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3.3.4 b2-adrenergic receptors
The human ?-ARs are classified into ?1,  ?2,  and ?3 subgroups, which serve as receptors for the
catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline). ?2-ARs are widely
distributed throughout the human bronchial tree, and particularly in the airway smooth muscle
(Barnes et al. 1982). In addition, inflammatory cells such as mast cells, monocytes, eosinophils, T
-lymphocytes, and neutrophils carry ?2-ARs (Johnson et al. 2002). Intracellular signaling after ?2-
AR activation is affected through Gs protein coupled adenylyl cyclase. cAMP induces airway
relaxation via mediating phosphorylation of bronchial smooth muscle regulatory proteins,
attenuation of cellular Ca2+ concentrations and inhibition of mediator release from mast cells.
Short-acting, inhaled, selective ?2-agonists, which activate these cytosolic effects, were
introduced over thirty years ago. To date, they still are among the most prescribed drugs
worldwide and remain the mainstay bronchodilators for asthma. Combinations of long-acting ?2-
agonists and corticosteroids appear to have additive and/or synergistic effects in inhibiting
inflammatory mediator release and the migration and proliferation of airway SMCs.
The relationship between ?-AR haplotype and acute and chronic pharmacodynamic
(bronchodilator) response is complex and widely studied (Taylor et al. 2005). There are two
common polymorphisms in the ß2-AR gene: Arg/Gly16 and Gln/Glu27. In vitro studies indicate
that the Gly16 allele enhances agonist-induced downregulation of the receptor, whereas the Glu27
allele enhances resistance to downregulation (Green et al. 1994, Hall et al. 1995, Hall 1999,
D'amato  et  al.  1998).  It  is  plausible  that  these  differences  in  receptor  regulation influence the
reactivity of airway smooth muscle in response to airway inflammation and thereby alter the risk
of asthma. However, epidemiologic studies have yielded conflicting results. A recent systemic
meta-analysis study found no evidence for the association of these ß2-AR polymorphisms in
adults (Thakkinstian et al. 2005). Instead, a recessive protective effect of Gly16 for children was
suggested. According to the haplotype analysis, there may be an interaction between the two sites
with  a  lower  risk  of  asthma  associated  with  the  Glu27  allele  (compared  with  Gln27).  The  risk
may be modified by the allele at position 16 (Thakkinstian et al. 2005).
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D. AIMS
Positional cloning of GPRA as an asthma susceptibility gene was the starting point of this study.
The biochemical properties of GPRA make it an excellent drug target candidate as an early
susceptibility factor in the pathogenesis of asthma and allergic diseases, but its role and functions
need to be understood in detail for any such applications. The identification of AAA1 in the
disease-associated region required its characterization in parallel with GPRA.
The specific aims of the study are
1) To clarify the role of AAA1 in the pathogenesis of asthma.
2) To  characterize  the  expression  of  GPRA  in  normal  human  tissues  and  during
inflammation in asthma.
3) To characterize the expression and function of GPRA utilizing a murine model of asthma.
4) To investigate whether GPRA associates with respiratory distress syndrome.
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E. MATERIALS AND METHODS
1. Patients and samples
Asthma family collection (I)
The patient recruitment and verification of diagnoses of subjects from Kainuu (a total of 254
families and 1015 study subjects), North-Karelia and Quebec were carried out as described
(Kauppi et al. 1998, Laitinen et al. 1997, Laitinen et al. 2001). Microsatellite genotyping was
performed in 103 trios (a total of 853 study subjects) and in all of the 86 pedigrees included in the
original  genome  scan  (Laitinen  et  al.  2001).  SNP  genotyping  was  carried  out  in  the  subset  of
families (106 trios, 361 study subjects) informative in the haplotype pattern mining (HPM)
analysis (Toivonen et al. 2000) for high serum IgE level. The relative risks for asthma and serum
IgE levels were computed both for the Kainuu and French- Canadian data sets among the
founders of the families (n=499 and n=402, respectively) to avoid weighing of any chromosome
segregating in the families.
Total serum IgE level was determined by Diagnostics CAP FEIA (Kabi Pharmacia) in
one batch for all the participants. Individuals from Kainuu and North-Karelia were divided into
two groups based on their total serum IgE level: high IgE responders (IgE > 100kU/L) and low
IgE responders (IgE < 100 kU/L).
Diagnosis of RDS (IV)
The study population for association analysis of GPRA and RDS consisted of 521 Finnish infants
born during the years 1996–2001 in the Oulu University Hospital. The clinical diagnosis of RDS
in the newborn infants was made by the presence of both clinical and X-ray definition. They
include requirement of supplemental oxygen and continuous distending airway pressures for at
least 48 hours after birth unless treated with exogenous surfactant in established respiratory
failure,  diffuse  reticulogranular  pattern  with  air  bronchograms  and  ground  glass  appearance  of
lung fields in the chest X-rays. Infants receiving surfactant therapy prior to radiography were
excluded. Neither pneumonia nor transient tachypnoea was diagnosed as RDS. BPD was defined
as requirement of supplemental  oxygen at  postmenstrual age of 36 weeks for those born before
32 weeks of gestation (Jobe and Bancalari 2001).
Human sputum samples (III)
2  atopic  and  6  non-atopic  patients  with  asthma  diagnosed  according  to  American  Thoracic
Society guidelines (ATS 1995) and 14 non-asthmatic subjects (6 atopic and 8 non-atopic) were
recruited for the study. Four subjects used inhalation steroid (beclomethasone) 800 mg per day
and one subject 1600 mg per day. The study was approved by the Ethics committee, Department
of Medicine, Helsinki University Hospital. Skin prick tests were made using 10 common inhalant
allergens and positive (histamine dihydrochloride, 10 mg/ml) and negative (solvent) control
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solutions. A subject was classified as atopic if any allergen induced a red spot of three
millimeters or more in diameter and control solutions gave expected results (Dreborg 1993).
Sputum was induced by inhalation of nebulized 5 % hypertonic saline via an ultrasonic
nebulizer (Rytilä et al. 2000). All subjects were pre-treated with 0.5 mg terbutaline (Bricanyl
Turbuhaler®) and peak expiratory flow was measured before the pre-treatment and after
induction.
Sputum processing was carried out as previously described (Rytilä et al. 2000). Cytospins
with a minimum of 300 nonsquamous cells were prepared and stained using the May-Grünwald-
Giemsa method or with the GPRA specific antibodies. All analyses were performed blind to the
clinical characteristics or treatment. The results are expressed as a percentage of individual cells
in relation to total nonsquamous cell count.
Peripheral blood mononuclear cells and eosinophils (III)
Peripheral blood cells were isolated from healthy volunteers or buffy coat donors by Ficoll
density gradient centrifugations (Biochrom KG). From the granulocyte fraction, erythrocytes
were first lysed and eosinophils were further separated by depletion of neutrophils using MACS
CD16 Microbeads (Miltenyi Biotec). Eosinophils were cultured for 24 h with 25 ng/ml
granulocyte-macrophage colony stimulating factor in complete RPMI 1640 medium
supplemented with 2 mM L-glutamine, 1 mM sodium puryvate, 1% MEM non-essential amino
acids and vitamins, 100 U/ml penicillin, 100 µg/ml streptomycin (all from Life Technologies)
and 10% fetal bovine serum (Sera-Lab). The purity of the eosinophil fraction was as high as 99 %
as detected by microscopic evaluation of cytospin preparations. Peripheral blood mononuclear
cells (PBMC) were cultured in complete RPMI 1640 over night and stimulated then for 6, 16, 28
or 48 h either with 10 ng/ml LPS or plate-bound anti-CD3 (1 µg/ml, clone OKT3, ATCC) and
anti-CD28 (2 µg/ml, PeliCluster clone 15E8, Sanguin). CD4+ T cells were isolated from PBMCs
using Dynal CD4 Positive Isolation Kit (Dynal) and rested o/n in serum free AIM-V medium
(Life Technologies, Basel, Switzerland). Monocytes were isolated by incubating freshly
separated PBMC’s in complete RPMI 1640 medium in cell culture bottle for 10-20 minutes.
Unattached cells were washed out and the adherent monocytes were trypsinized, washed and
rested o/n in complete RPMI 1640.
Experimental mouse models (I, III)
BALB/c female mice, age 6–8 weeks, free of specific pathogens, were obtained from M&B, Ry.
The mice were housed under pathogen-free conditions and maintained on OVA-free diet. All
experiments  conducted  were  approved  by  the  Animal  Experimental  Committee  of  the  State
Provincial Office of Southern Finland.
Two models were applied. In the first model with OVA-sensitization and challenge, mice
were sensitized intraperitoneally on days 1 and 10 with 20 µg grade V OVA (Sigma-Aldrich)
adsorbed to 2 mg of alum adjuvant (Pierce Biotechnology Inc.) diluted in saline (III). In the
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second model used for GPRA mRNA expression studies, mice were sensitized and challenged
with OVA as above in combination with 7 intranasal applications of Stachybotrys chartarum
mold (NRRL 6084) over a period of 22 days (I). In both models, unsensitized and naïve control
mice received 200 µg of saline-diluted alum intraperitoneally. Challenge of the unsensitized
control and OVA-sensitized mice consisted of a 40-minute exposure to 1% (wt/vol) OVA in
saline on days 20, 21, and 22. All mice were exposed to aerosol in an exposure chamber
connected to the outlet  of  a  six-jet  atomizer  that  delivered  an  aerosol  of  particles with a mean
diameter of 0.3 µm (TSI Inc.).
The mice were killed by CO2 asphyxiation  at  day  23.  The  blood  was drained from the
vena cava. The lungs were lavaged with phosphate-buffered saline (PBS) via the tracheal tube (1
x 800 ml for 10 s). The bronchoalveolar lavage (BAL) sample was cytocentrifuged (Cytospin,
Shandon Ltd) onto a slide and the cells were stained with the MayGrünwald–Giemsa (MGG)
stain. The cell population on the cytospin slide was counted under light microscope. The left lung
was removed for mRNA isolation, quick-frozen and kept at ?70°C. For histologic examination,
the right lung was perfused with 10% formalin and then excised en bloc.  The  lungs  were
embedded in paraffin, cut into 5-mm-thick sections, affixed to microscope slides and
deparaffinized. The slides were stained with haematoxylin and eosin and examined under light
microscope.
Cell cultures (II, III)
COS-1 cells (ATCC) were cultured in Dulbecco’s modified Eagle’s medium
(GibcoBRL/Invitrogen) supplemented with 10% fetal bovine serum (Perbio), 1%
Penicillin/Streptomycin (GibcoBRL) and 1x non-essential amino acids (GibcoBRL). Human lung
epithelial carcinoma cell line NCI-H358 (ATCC) and was cultured in RPMI 1640 medium
(GibcoBRL) supplemented with 1 mM sodium puryvate (GibcoBRL), 10% fetal calf serum
(Biological Industries, Kibbutz Beit Haemek, Israel), and 1% Penicillin/Streptomycin. BEAS-2B
cell line originating from normal human bronchial epithelium was cultured in Basal Medium
(Cambrex) supplemented with Bullet Kit (Cambrex). Myoblast cells were isolated from normal
human skeletal muscle (kindly provided by Dr. P. Salmikangas) and cultured in Dulbecco’s
modified Eagle’s medium (Gibco BRL) supplemented with 15% fetal bovine serum (Perbio), 4%
Ultroseer G (BioSepra,) and 1% Penicillin/Streptomycin. Murine macrophage cell line, RAW
264.7 (ATCC) was cultured in RPMI 1640-medium supplemented with 10% of heat inactivated
fetal bovine serum, 1% of L-glutamine and 1% of Penicillin–Streptomycin antibiotic mixture (all
from Gibco/Invitrogen).  All  cell  lines  were  cultured  at  37  ºC in  a  CO2 conditioned, humidified
incubator.
In order to obtain GPRA-A stable cells, GPRA-A cDNA was cloned into a pQM vector
under CMV promoters (produced by Quattromed AS). 293H cells were transfected with
Lipofectamine 2000 (Gibco BRL) and clones were cultured under puromycin selection. GPRA-A
positive clones were characterized by RT-PCR or real-time PCR, and Western blotting.
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Minimum of three different GPRA-A positive and negative clones and parental 293H cell line
were used for different studies in which the clones were cultured in 293 SFM II medium (Gibco
BRL) with or without 0.8 µg/ml puromycin (Sigma-Aldrich, St. Louis, MO).
2. Association analyses
Genotyping, SNP discovery and sequencing (I, IV)
In order to create a dense map of polymorphic markers spread evenly across the 7p14-p15
linkage region, the publicly available genomic sequences for potentially polymorphic tandem
repeats were screened (Polvi et al. 2002). All microsatellite markers and deletion/insertion
polymorphisms found in the critical region were genotyped using fluorescently labeled primers in
gel electrophoresis on an ABI377 sequencer. SNP genotyping was carried out using two different
methods: single base pair extension with the chemistry of Molecular Dynamics on a MegaBASE
1000 sequencer (Molecular Dynamics) or PCR (using 20 ng of genomic DNA as starting
material) followed by restriction enzyme digestion. Altogether 8 individuals were resequenced
for nonrepeated DNA segments by direct sequencing of PCR products. Purified PCR fragments
(Quickstep 2 PCR purification Kit, Edge BioSystems) were sequenced from both directions using
ABI Prim3100 (Applied Biosystems) sequencer and dye-terminator chemistry. We assembled
forward and reverse sequence reads using the Gap4 program (Staden Package software). All the
markers were in Hardy-Weinberg equilibrium and observed Mendel errors were less than 0.1%.
For the association study of GPRA with RDS (IV), DNA was extracted from a 3-mm disk
punched from a blood spot dried on a filter paper. Whole genome amplification was carried out
with  the  extracted  DNA  using  the  improved  primer  preamplification  (I-PEP-L)  method  and
genotyped using the Sequenom platform (Hannelius et al. 2005, Sun et al. 2005). Seven
haplotype tagging intronic SNPs in the GPRA gene (Melen et al. 2005, Table 5) were genotyped
using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF) technology. Primers were designed with the SpectroDesigner software (Sequenom GmbH,
USA). All samples were analyzed in a sex-specific assay (AMELXY, MWG-Biotech AG) to
validate the sample logistics. Three positive and three negative controls were included in each 96
well DNA plate, and all genotyping results were confirmed independently by two persons.
Statistical and computational analyses (I, IV)
In the asthma studies (I), haplotypes were analyzed with the HPM software (Toivonen 2000),
whereas the SNPHAP program v.1.2.1 (http://www-
gene.cimr.cam.ac.uk/clayton/software/snphap.txt) was utilized in the RDS studies (IV).
HPM is a data mining-based algorithm that searches for shared patterns among haplotypes, scores
each marker location for the number of shared patterns, and evaluates empirically the
significance of the scores by a permutation test. Its utility for locating genes within haplotype
data has been shown (Sevon et al. 2001). Linkage disequilibrium between SNP markers was
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calculated and the graphical output (Laitinen et al. 2001) was produced by the Haploblocks
software (M. Zucchelli and J. Kere, unpublished).
SNPHAP uses an expectation maximization (EM) algorithm to calculate maximum
likelihood estimates of haplotype frequencies from population-based unphased genotype data.
SNPHAP lists the individual predicted chromosomewise haplotype assignments and their
probabilities. The single-marker data and pairwise linkage disequilibrium (D’) values were
calculated by Haploview v. 3.2 available at http://www.broad.mit.edu/mpg/haploview/ (Barrett
2005). Haplotype comparisons were performed using a c2 test in a 2x2 contingency table (Arcus
Quickstat Biomedical v. 1.0).
3. Gene discovery
Exon prediction (I, II)
Exon predictions were performed by the GENSCAN (http://genes.mit.edu/GENSCAN.html)
software using genomic clones AC005493.1 and AC005826.1 (690 kb) (Polvi et al. 2002) as one
block. Predictions were performed for both unmasked and masked sequence. In the latter, the
repetitive sequences were masked using the Repeat Masker Service
(http://repeatmasker.genome.washington.edu/).
RACE-PCR (I, II)
To  generate  3’  and  5’  cDNA  ends,  rapid  amplification  of  cDNA  ends  (SMART  RACE)  was
performed using human testis cDNA and Human Marathon-Ready Fetal Thymus cDNA
(Clontech) according to the manufacturer’s protocol for the SMART RACE cDNA Amplification
Kit (Clontech). RACE-PCR products were cloned using pGEM-T Easy Vector system (Promega)
or TOPO TA Cloning kit (Invitrogen) and plasmid DNA was purified using QIAprep Spin
Miniprep Kit (Qiagen). The purified RT-PCR products and the cloned RACE-PCR products were
verified by automated sequencing with dye-terminator chemistry (ABI Prism3100, Applied
Biosystems, Inc).
Cloning (I)
Nested PCR amplification using two set of primers was used in cloning of the full length cDNAs
for GPRA splice variants A and B. Primary PCR amplifications were performed in 25 ml volumes
using 2.5 ml Human Brain Marathon-Ready cDNA (Clontech) as template, 1x DyNAzyme EXT
buffer (containing 1.5 mM MgCl2), 0.2 mM deoxy-nucleotide triphosphates (Finnzymes), 0.52
mM primers, 5% dimethyl sulfoxide and 0.5 U DyNAzyme EXT (Finnzymes) under the
following conditions: 94°C for 4 min, 38 cycles of 94°C for 30 s, 65°C for 30 s, 72°C for 1 min
followed by final extension of 72°C for 10 min. The aliquot of primary PCR product was re-
amplified by 30 PCR cycles under the same conditions as above.
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PCR products were cloned into pCR 2.1 TOPO -vector using TOPO TA cloning kit
(Invitrogen) according to manufacturer’s instructions and plasmid DNA were purified using
QIAprep Spin Miniprep Kit (Qiagen). The cloned RT-PCR products were verified by automated
sequencing with dye-terminator chemistry (MegaBACE 1000, Amersham Biosciences).
In vitro translation (I)
In order to investigate whether AAA1 is translated to any polypeptide, in vitro translation experiments
were performed. Capped RNA of AAA1 gene variants I and III were transcribed from DNA constructs
with  T7  RNA  polymerases  (mMESSAGE  mMASCHINE  system,  Ambion,  USA).  Translation  was
performed with rabbit reticulocyte lysate translation machinery (Riboprobe in vitro translation system,
Promega) in the presence of S35 -labeled methionine (PerkinElmer) in the reaction mixture. The
Xenopus elongation factor a (pTRI-Xef) DNA template was used as a positive control for transcription
and translation. In negative control, water was used instead of DNA. The translated polypeptides were
detected by autoradiography after Tris-Tricine SDS-PAGE.
Statistical and computational analyses (I)
The transmembrane topology and putative N-glycosylation sites of GPRA protein were predicted
using the PredictProtein (http://cubic.bioc.columbia.edu/predictprotein/submit_def.html#top) and
the TMpred (http://www.ch.embnet.org/software/TMPRED_form.html) softwares. In protein
homology comparisons, the BlastP (http://www.ncbi.nlm.nih.gov/blast/) and T coffee
(http://www.ch.embnet.org/software/TCoffee.html) softwares were used.
4. mRNA expression studies
Northern blot hybridization (I)
Human multiple tissue 8-lane Northern blot (Clontech) were hybridized using a[32P]-dCTP
random-labeled 1285-bp cDNA probe (comprising the full-length GPRA). The probes were
generated by PCR amplification of human testis cDNA (Clontech; MTN 8-lane blot) and human
brain cDNA (Invitrogen; MTN 12-lane blot), respectively. Prehybridizations were performed in
ExpressHyb solution (Clontech) for 3 hours at 65°C. Herring sperm DNA (100 µg/ml) was used
as  the  blocking  reagent.  The  membranes  were  washed  with  2  x  SSC and  0.05  % SDS at  room
temperature and then exposed to X-ray film at –20 °C for 3 d (GPRA) and for 1 h (b-actin
control).
Sample preparation, RNA extraction and cDNA synthesis (III, IV)
The  subjects  for  mRNA  analysis  of  the  nasal  scratch  samples  were  treated  in  the  Hospital  for
Children and Adolescents, Helsinki University Central Hospital, during the years 2004-2005
(IV).  GPRA  mRNA  expression  was  studied  in  the  nasal  respiratory  epithelium  of  6  term
(gestation age 39.3±1.2 weeks, mean ± SD; birth weight 3480±200 g; male female ratio 3/3) and
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7 preterm infants (gestation age 26.4 ± 1.5; 980 ± 180; 2/5), and 10 adults (41.4 ± 8 years; 10/0)
with no history of asthma or atopy. In the preterm infants the scratch test was performed twice, at
the age of 1 - 4 h and 21 - 48 h as described (Helve et al. 2004). In the first sampling, the
postnatal age of the subjects varied between 97 ± 22 min in the term and 62-175 min in the
preterm subjects.  The nasal samples were gathered under direct vision by scraping the nasal
epithelium using a Rhino-Probe (Arlington Scientific), dispersed into lysis buffer and stored at –
80°C as described (Helve et al. 2004). Subsequently, total RNA was extracted with RNeasy kit
(Qiagen) and quantified using RiboGreen RNA Quantitation Kit according to the manufacturer´s
instructions (Molecular Probes).
For analysis of human blood cell preparations (III), total RNA from 0.1 - 5x106 cells was
lysed followed by storing and RNA extraction as described above. For analysis of murine lung
samples, total RNA from lungs was extracted using Trizol Reagent (GIBCO BRL) according to
the manufacturer's protocol. The amount of RNA was quantified by spectrophotometry
(GeneQuant II/Pharmacia Biotech).
cDNA synthesis was performed with MultiScribe reverse transcriptase according to the
manufacturer's instructions (Applied Biosystems) using either random hexamers or oligo dT
primers for 60 min at 48 °C, after which the enzyme was inactivated at 95 °C for 5 min.
Real-time quantitative RT-PCR assay (I, III, IV)
The quantitative real-time RT-PCR was performed by AbiPrism 7500 or 7700 Sequence
Detection System Sequence Detector System (Applied Biosystems) according to the
manufacturer’s instructions. The sequences of the human and mouse GPRA primers and probes
were designed by PrimerExpress software (ABI). Quantitative real-time PCR of human blood
cell samples (III) was performed applying SybrGreen chemistry (Applied Biosystems), whereas
the Taqman assay was utilized in measuring GPRA mRNA expression in nasal scratch samples
(IV) and in murine whole lung (I) and RAW cell line 264.7 samples (III). The sequences for the
primers and the probes are given in Table 3.
One ml of the cDNA sample was amplified for GPRA detection in a final volume of 25 ml
containing 12.5 ml of TaqMan Universal PCR Master Mix and AmplitaqGold polymerase
(Applied Biosystems), 300 nM forward and reverse primers and 200 nM probe. After an initial
incubation at 95 °C for 10 min to activate the DNA polymerase, 40 cycles were performed for 15
s at 95 °C and for 1 min at 60 °C. Cytokeratin 18 (CK18) was used as an epithelial marker
(GPRA:CK18, ng/fmol) in nasal scratch samples (IV). In murine whole lung (I) and RAW cell
line 264.7 samples (III), PCR primers and probes for the housekeeping genes b-actin or 18S
rRNA were obtained as predeveloped assay reagents and were ordered from Applied Biosystems.
In human blood cell samples (III), elongation factor (EF) 1a was  amplified  as  an  endogenous
reference gene. The relative gene expression differences were calculated with the comparative
??CT method.
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Table 3. Primers and probes for real-time RT-PCR. Abbreviations: EF-1, elongation factor 1
Name Forward Reverse
GPRA-A CCTGCAGGGAGCAAAGATCA AATCTGCATCTCATGCCTCTCA
GPRA-B CCTCAACGAGAGAACTGGAAG AGAGCTGTCACCTTGGAAGAG
NPS CAAAATGATTAGCTCAGTAAAACTCAATC GGAACTGGATAACACCAAAACACA
EF-1 CTGAACCATCCAGGCCAAAT GCCGTGTGGCAATCCAAT
CAAAGGCAAAAATCAAGGCTATC AGGTTGAAATTGTCCAAAATGTCAGPRA
probe 6-FAM-5' CATCATCATTCTTGCCTTCATCTGCTGTTG-3'-TAMRA.
GGCTCATCTCTAAGGCAAAAATCA ACGCTCCTTGGTGTCTGGAAGpra
probe 6-FAM-5' CGTCATAATCCTTGCTTTCATCTGCTGCTG-3'-TAMRA
In situ hybridization (II)
Antisense and sense probes from DNA templates of AAA1 (Image clones V3: 482785 in
PBluescriptR, 3387 bp, V1 232825 in pT7T30-Pac1, 3482 bp) as well as GPRA and NPS (full-
length  GPRA-A and NPS cDNA in  pCMV-Script  vector) were transcripted by T3 or T7 RNA
polymerases in the presence of digoxigenin-11-uridine-5´-triphosphate (Dig-11-UTP, Roche) by
MAXIscript in vitro transcription kit (Ambion) according to the manufacturer´s instructions. The
NPS cDNA sequences  were  amplified  by  PCR from a  human pancreas  cDNA sample  (Human
Multiple Tissue cDNA Panel, BD Biosciences)
Non-radioactive in situ hybridization on tissue sections was performed with Ventana
DiscoveryTM device. Briefly, the samples were frozen sections or deparaffinized with heat
treatment followed by post-fixation and RiboClear pre-treatment. Samples were protease treated
for 18 min and hybridized for 6 h at 65 °C with both antisense and sense probes. Slides were then
washed  three  times  with  0.1X  SSC  (15  mM  NaCl,  150  nM  Sodium  citrate,  pH  7.0)  at  75 °C
followed by the detection step, which includes 20 min incubation with biotinylated anti-DIG
antibody (Jackson ImmunoResearch Laboratories) and 2 h incubation with the BCIP/NBT
substrate. After color reaction the slides were washed, dehydrated and mounted with Mountex
(HistoLab). All reagents for DiscoveryTM are provided by Ventana Medical Systems except for
protease K (Roche), which was used at a concentration of 350 ng/ml.
Characterization of the alternatively spliced GPRA transcripts (I, II)
Poly A+ RNAs from human lung epithelial carcinoma cell line NCI-H358 (ATCC) were isolated
by Dynabeads mRNA DIRECT Kit (Dynal) according to the manufacturer’s instructions and
subsequently reverse transcribed to cDNA by using SMART RACE cDNA amplification Kit (BD
Biosciences). PCR was performed in 20 µl volume using 2.0 µl NCI-H358 cDNA as template,
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1X PCR Gold buffer, 1.5 mM MgCl2, 0.2 mM dNTPs (Finnzymes, Espoo, Finland); 1 mM of 3’-
tgagcaattgataactctgtgggtcctc-5’ and 3’-gaatggtggggaaggaaggcgttt-5’ or 3’-
tgagcaattgataactctgtgggtcctc-5’ and 3’-ggccatcctgctgtgacccatttt-5’; and 0.5 U AmpliTaqGold
(Applied Biosystems, Foster City, CA) under the following conditions: 94°C for 10 min; 40
cycles of 94°C for 30 s, 66°C for 30 s, 72°C for 1 min followed by final extension of 72°C for 10
min. PCR products were cloned into the pCR 2.1 TOPO -vector using TOPO TA cloning kit
(Invitrogen) according to manufacturer’s instructions and plasmid DNAs were purified using
QIAprep Spin Miniprep Kit (Qiagen). The cloned RT-PCR products were verified by automated
sequencing with dye-terminator chemistry (MegaBACE 1000, Amersham Biosciences).
5. Protein expression studies
Antibodies and peptides (I- IV)
Four  specific  antibodies  against  the  amino  terminus,  the  third  cytoloop  and  the  two alternative
carboxy termini of GPRA were raised by immunizing rabbits with the following peptides:
TEGSFDSSGTGQTLDSSPVAKKG (a KKG core containing multiple antigen peptide
corresponding to the nucleotides 16-76 of the N-terminus of GPRA), SSYNRGLISK
(corresponding to the residues 258-267 of the third cytoloop), CREQRSQDSRMTFRERTER
(corresponding to the resudies 341-359 of the variant A) and CPQRENWKGTWPGVPSWALPR
(corresponding to the nucleotides 357-377 of the variant B). A TEGSFDSSGTGQTLDSSPVAC-
peptide for purification of the amino terminal antibodies as well as GPRA-N multiple antigen
peptide and GPRA-B peptide synthesis were purchased from the University of Helsinki and
antibody production from the University of Oulu. GPRA-A and cytoloop 3 peptide syntheses and
antibody production were purchased from Sigma-Genosys Ltd. GPRA-B peptide was conjugated
to KLH carrier with Imject Maleidine Activated mcKLH kit (Pierce) and purified by gel
filtration, whereas the conjugation of GPRA-A and GPRA-CL3 peptides to KLH was carried out
in  Sigma-Genosys  Ltd.  To  further  investigate  the  possible  translation  of  the AAA1 gene,  a
polyclonal antibody against the constant region (YVRRNAGRQFSHC) of the gene was produced
in rabbits as above (Sigma-Genosys Ltd). A total of 6 immunizations were performed at 2 weeks
intervals using a total of 2 mg of KLH-conjugated peptide as immunogen.
The sera were analyzed by enzyme-linked immunosorbent assay using the uncoupled
peptides immobilized onto the nitrocellulose filters as antigens. Positive antisera were affinity-
purified using Sulfolink (GPRA-A, GPRA-B and GPRA-N) or Ultralink kits (GPRA-CL3)
(Pierce) and analyzed by immunoblotting of recombinant fragments expressed with the pGEX
4T-3 GST fusion expression vector (Amersham Biosciences) as glutathione-S-transferase (GST)
fusion protein in Esterichia coli except for the C-terminal tail of the A isoform which was
expressed  as  a dihydrofolate reductase (DHFR) fusion protein (Qiagen). Blocking experiments
using 10 molar excess of free peptide as a competitor were also performed to demonstrate
antibody specificity.
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The goat polyclonal glyseraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz) and the horseradish peroxidase
-conjugated secondary antibodies from Jackson ImmunoResearch Laboratories Inc. Monoclonal
anti-myc and anti-HA antibodies were purchased from Berkeley. The non-immune rabbit IgG
fraction was obtained from DAKO. NPS polypeptide (SFRNGVGTGMKKTSFQRAKS) was
synthesized by MedProbe.
Transient transfections (II)
COS-1 cells were transiently transfected using Fugene6 transfection reagent (Roche) according to
the manufacturer’s protocol. The empty pCMV vector, beta-gal-pCMV, and myc-tagged
luciferace-pCMV vectors (Stratagene) were used as controls. In transfections, 2.5 µg of DNA and
12 µl of Fugene6 (GPRA-C, -D, -E, -F, and -Bshort vectors) or 2.0 µg of DNA and 8 µl Fugene6
(GPRA-A and -B vectors) were used for 5 x 106 cells in 35 mm cell culture dishes.
In order to study the effects of AAA1 open reading frames or the various GPRA splice
variants on the translocation of the full-length GPRA-A or -B receptors to the plasma membrane,
COS-1 cells were cotransfected with myc-tagged HA-tagged AAA1 or GPRA-A or -B with 0.3,
1, 3, and 10-fold amount of pCMV-GPRA-A, -B, -Bshort, -C, -D, -E or -F. The empty pCMV-
vector and b-gal  vector  were  used  as  controls.  In  all  transfections,  2  µg  of  DNA  and  8  µl  of
Fugene6 per 5 x 106 cells were used. The cells from one well of 6-well plate were divided into
16-wells of 96-well plate 24 h after transfection. The cells were analyzed with cell-based Elisa
assay or immunofluorescence staining 24 h or 48 h after transfection. In addition, the AAA1-
transfected cells were analyzed with immunoblotting and RT-PCR.
Cell-based Elisa assay (II)
Transfected cells were fixed with 3.5% paraformaldehyde in PBS for 15-20 min at room
temperature. Cells were blocked with TBS (25mM Tris-150 mM NaCl, pH 8.0) containing 2%
powered milk and 1% goat normal serum at 37 ºC for 30 min. Cells were then incubated with
1:1000 dilution of anti-myc- antibodies for 1 h at 37 ºC, washed three times with TBS and
thereafter incubated with a dilution of 1:2000 of horseradish peroxidase-conjugaded anti-mouse
IgG antibodies for 30 min at room temperature. TMB-substrate (Sigma Genosys) was added to
cells  for  3  to  6  min.  The  reaction  was  stopped  by  adding  an  equal  amount  of  1.5  M  HCl  and
absorbance was measured at 450 nm. Half of the cells were permeabilized in order to detect the
total expression level of the corresponding construct by adding 0.5% Triton-X-100 in PBS for
10-15 min after fixation. The results were normalized using the absorbance values obtained from
pCMV and beta-gal control experiments.
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Immunofluorescence stainings (II)
Transfected cells grown on coverslips were fixed in 3.5% paraformaldehyde in PBS,
permeabilized with 0.1% Triton X-100, blocked with PBST (PBS/ 0.01%/ Tween 20) containing
0.5% bovine serum albumin at room temperature for 30 min, and then incubated in PBST/ 0.1%
bovine serum albumin with anti-GPRA-A, anti-GPRA-B, or anti-HA antibodies for 1 h at room
temperature and then washed three times with PBST. Thereafter, the cells were incubated in
PBST with (10 µg/ml) Alexa Fluor 488 goat anti-rabbit IgG or Alexa Fluor 488 goat anti-mouse
IgG antibodies (Molecular Probes) for 30 min at room temperature and washed three times with
PBST. Samples were visualized by fluorescence microscopy.
Western blot analysis (II, III)
For western blot analysis of human tissues (II), lysates from spleen, skeletal muscle, uterine
muscle, colon muscle, kidney, colon epithelium, testes, and prostate were obtained by
mechanically homogenizing the frozen tissue samples in 10 mM Tris HCl, 100mM NaCl, 2 %
Triton X-100 buffer with with Complete Mini -protease inhibitors (Roche). Human cell lysates
from various cell lines were obtained by homogenizing the cell samples in RIPA-buffer (1xPBS,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) with Mini Complete protease
inhibitors (Roche). For detection of PBMC samples (III), 1x106 cells were lysed directly into
sample buffer. For crude membrane preparations (II), transfected COS-1 cells were harvested in
TE buffer (10 mM Tris, 0.1 mM ethylenediaminetetraacetic acid, pH 7.5). The membrane
fractions were separated by suspending cell pellets in TE buffer with 0.32 mM sucrose,
homogenizing mechanically, and centrifuging for 15 min at 380 g at 4 ºC. Supernatant was
further centrifuged for 30 min at 40600 g at 4ºC. The pellet was suspended into sucrose-free TE
buffer and centrifuged as above. The amount of protein was measured with the BCA Protein
Assay Reagent kit (Pierce).
Fifty mg of the protein lysates or 1x106 cells  were  run  on  reducing  12.5  % SDS-PAGE
gels and electroblotted to the PVDF membrane according to standard procedures. Nonspecific
protein binding was prevented by incubating the membrane with 5 % milk in 0.1 % Tween 20 in
TBS (TBST). Antigenic sites were revealed by incubating the membrane with the antibodies or
preimmune serum followed by the horseradish peroxidase -conjugated goat anti-rabbit secondary
antibody (Jackson ImmunoResearch Laboratories Inc.) in 5 % milk in 0.1 % TBST. The bands
were revealed by the ECL detection kit (Amersham Biosciences). Negative controls did not show
specific reactivity.
In human PBMC samples (III), the relative GPRA-A and -B expression was quantified after
equalizing with the relative expression of GAPDH used as an endogenous reference gene.
Syngene GeneTools software (Synoptics Ltd.) was used for detecting differences between
intensities of the corresponding lanes. The unstimulated cells received a relative band intensity
value of 1.0.
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Immunohistochemistry (I-IV)
Formalin-fixed, paraffin-embedded specimens of normal adult human bronchus, skin and colon
as well as human normal tissue array slides (MaxArray, Zymed Laboratories Inc.) containing 30
different tissues were used for immunohistochemistry. Bronchial biopsies from 10 control
subjects and 8 asthmatic patients,  who used either sodium cromoglycate or short-acting b-AR -
agonist, were also studied. The bronchoscopic examination and biopsy-taking (Laitinen A. et al.
1997) have been approved by the appropriate Ethical Review Board. All the subjects for RDS
and BPD studies were treated in the Hospital for Children and Adolescents, Helsinki University
Central Hospital, during the years 1992-2000. The tissue samples were obtained from autopsies
performed within 2 days of death. Fetuses were aborted in mid-pregnancy because of severe
extrapulmonary anomalies. The term control group with macroscopically and microscopically
normal lungs consisted of newborns who died of causes other than lung diseases at the age of <24
hours. The RDS group consisted of patients who died at the age of 3-16 days. The infants with
severe BPD died at the age of 2.5-10 months. All the study protocols have been approved by the
ethics committees of the participating centers, and a signed consent was obtained from the parents
of the subjects.
For pre-treatment, slides were deparaffinized by xylene-treatment followed by decreasing
alcohol series. The slides were heated in microwave oven in 10 mM citrate buffer, pH 6.0 for 5
min and stained using the enzymatic ABC (Avidin and Biotinylated horse-radish peroxidase
macromolecular Complex) method (Vectastain Elite ABC kit, Vector Laboratories). The color
reaction was revealed by 3-amino-9-ethylcarbazole (Vector Laboratories). Omission of primary
antibody and staining with the nonimmunized sera was used as negative control for parallel
sections. Neither of these controls showed any immunoreactivity.
6. Functional studies
GPRA-A overexpressing cell line (II, III)
GPRA activation in parental 293H cells, in three GPRA- positive and two negative clones was
determined using the non-radioactive GTP-Eu binding assay (Perkin Elmer) according to
manufacturer´s instructions in the absence or presence of 1 mM NPS. For the cell  growth assay
(II), GPRA-A positive cells were seeded at a concentration of 0.3 x 106 cells/ml and cultured in
293 SFM II medium (GibcoBRL) containing 0.8 µg/ml puromycin. At days 2 and 4, cell numbers
were counted. For a quantitative cell number assay, GPRA-A positive and negative clones were
split into 96-well plates into a concentration of 2 x 104 cells per well. 1 µM NPS was added and
the relative amount of viable cells was determined after 3 days by using CellTiter 96 One
solution Cell Proliferation Assay (Promega, Southampton, UK).
To study NPS-mediated signaling events (III), cell clones were divided into serum-free
SFM II medium at a density of 2.5 × 105 cells/ml. The cells were loaded with 4 mM Fluo-3, AM
(Molecular Probes) for 15 min at 37 °C followed by a 20 min incubation at room temperature.
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After two washes, 50000 cells were seeded into 96-well plates and Ca2+ -dependent fluorescence
traces (1 data-point/s, exitation at 488 nm) were measured by Fluostar Optima (BMG
Labtechnologies) microplate reader. NPS (1 mM) was added prior to measurement at 535 nm.
For cAMP assay (III), the GPRA overexpressing cell clones and 293H parental cells were
divided into cell culture medium at a density of 5 × 104 cells/well and incubated for 3 h at 37 °C.
Thereafter, increasing concentrations (0.1-10 mM) of NPS were added to the cells for 20 min. The
cells were lysed with cAMP detection lysis reagent for 10 min and stored at –80 ºC. Before
storing, viability of the cells was confirmed with Trypan blue exclusion method. Total cellular
cAMP was detected with cAMP Biotrak Enzyme immunoassay System (Amersham Biosciences)
according to the manufacturer`s instructions. The reactions were stopped with 1 M H2SO4 and the
absorbance values were measured at 450 nm. Duplicate wells were studied and half of the total
end volume of 200 µl was used for measurements.
RAW 264.7 mouse macrophage cell line (III)
For the cell attachment assay, microtiter wells (Nunc) were  coated  overnight  with  20  ng/ml  of
fibronectin, 5 ng/ml of collagen or 100 ng/ml of poly-L-lysine at +37°C. The wells were blocked
for 60 min with 0.5% bovine serum albumin in PBS. RAW 264.7 cells were harvested by
scraping, washed and resuspensed into RPMI medium at a density of 3.5 × 105 cells/ml. The cells
were preincubated in the presence or absence of 1µM NPS for 30 min on ice. Subsequently,
3.5 × 104 cells were seeded onto the wells, and the plates were incubated for 50 min at 37°C.
After three washes with PBS, the cells were counted using CyQuant reagent (Molecular Probes)
and Victor2 plate reader (Perkin-Elmer) at excitation/emission wavelengths of 485/530 nm.
Chemotactic migration was investigated using 24-well Transwell chambers (Corning) and
polystyrene cell culture inserts with 6 mm pore size. Transwell culture chambers were coated
overnight  with  fibronectin  (20  ng/ml)  at  +4°C.  Cells  were  washed  once  with  serum-free  RPMI
and seeded to cell culture inserts at a density of 105 cells/insert  in  serum-free  RPMI.  Lower
chambers contained 200 ng/ml monocyte chemoattractant protein 1 (R&D Systems) or 1 mM
NPS in serum-free RPMI as chemoattractants, while media alone was added to the control
chambers. The cells were allowed to migrate for 2 h at + 37ºC. The upper side of the membrane
was wiped off and the migrated cells in the lower side were lysed into 400 ml of CyQuant reagent
(Molecular Probes). Fluorescence was measured with the Victor2 plate reader as above.
Random cell migration was measured by a ‘wound healing assay’. RAW 264.7 cells were grown
to confluency for 14 days on a 24-well plate in RPMI with 10% serum. Cells were washed once
with PBS and pipet tips were used to scrape a cell free zone with constant width in the middle of
the wells. Cells were washed once more with PBS and 1 mM NPS in serum-free RPMI was added
to the wells to induce cell migration, while media alone was added to the control wells. The cells
were allowed to migrate for 24 h at +37°C followed by analysis with light microscopy. The
experiment was repeated three times using 6 parallel wells.
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Phagocytosis activity of cells was measured with Vybrant Phagocytosis Assay Kit
(Molecular Probes). Briefly, 1x105 cells were seeded to the 96 well plates and incubated in RPMI
for  1  hour  in  the  presence  or  absence  of  1 mM  NPS  followed  by  2-h  incubation  with  the
fluorescein-labeled Escherichia coli. The fluorescence from noninternalized bacteria was then
quenched by the addition of trypan blue. Subsequently, the samples were assayed with a Victor2
microplate reader with filters for detection of fluorescein. Tutftsin (Sigma-Aldrich) at a
concentration of 1 mg/ml was used as a positive control. In order to identify the specific signaling
pathways involved in the NPS-mediated phagocytosis, the specific inhibitors BAPTA-AM,
bisindolylmaleimide I and H-89 (Calbiochem) for intracellular Ca2+, protein kinase C and protein
kinase A, respectively, were incubated with the respective suboptimal concentrations of 50 µM, 1
µM and 1 µM in the presence of 1 mM NPS. The inhibitors were diluted into dimethyl sulfoxide.
The results were verified by fluorescence microscopy under a magnification of 6300.
Briefly, 4x105 cells  were  seeded  on  coverslips  and  incubated  for  1  hour  in  the  presence  or
absence of 1 mM NPS followed by 2-h incubation with the fluorescein-labeled Escherichia coli.
The fluorescence was not quenched with trypan blue. After two washes with PBS, the cells were
fixed with 3.5% paraformaldehyde in PBS, mounted and visualized by fluorescence microscopy.
Statistical analysis (II, III, IV)
All data are expressed as mean ± standard error of mean (SEM) unless stated otherwise. Student's
t test and analysis of variance were used for parametric comparisons, whereas Mann-Whitney and
Kruskal-Wallis tests were used for nonparametric comparisons.
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F. RESULTS
1. POSITIONAL CLONING OF GPRA AND AAA1
To identify the gene(s) accounting for the observed associations, the linkage region was refined
by a hierarchical genotyping design until a 133-kb risk-conferring segment was discovered on
chromosome 7p14.3. Briefly, the 20-cM linkage region was narrowed down by genotyping 76
microsatellite markers in families from Kainuu. Haplotype patterns spanning 12 microsatellite
markers within 3.5 cM were associated with high serum IgE. At the second round of fine
mapping, genotyping of 10 additional microsatellites implicated a 301-kb haplotype pattern. At
the next cycle, five microsatellites and 13 SNPs with the highest associations were genotyped to
reveal a 47-kb haplotype pattern (10 markers). The boundaries of this critical region were
determined by genotyping additional SNPs in 131 trios. In data analysis, strongest associations
were observed within a conserved 133-kb pattern.
Two other data sets from Quebec and North Karelia were genotyped to replicate the
results in independent case-control cohorts. Most of the SNPs were  shared,  but  some  of  them
differed from the ones discovered in Kainuu population. In the three populations, 13 SNPs across
the most conserved 77 kb produced seven alternative haplotypes (with frequencies >2% in the
population). Sequencing the 133-kb segment from six additional individuals (including an
asthmatic subject from Quebec and a North Karelian with high IgE), each homozygous for a
different haplotype, confirmed that each of the haplotypes yielded unique SNP compositions. A
phylogenetic analysis confirmed that the three risk haplotypes were evolutionary closely related
and distinct from the four non-risk haplotypes in all three populations. In the Finnish population,
more than half  of  the  asthma patients  carried  the  three  risk  haplotypes  as  opposed  to  only  one
third of the healthy subjects. The relative risk effect for high serum IgE was 1.4 among H4/H5
carriers in Kainuu, whereas the homozygous H2 haplotype carriers had a 2.5-fold risk for asthma
in the Canadian population.
Utilization of gene expression analyses and computer algorithms for gene prediction over
the disease-associated region revealed two previously uncharacterized genes named GPRA (G
Protein coupled Receptor for Asthma susceptibility) and AAA1 (Asthma Associated Alternatively
spliced gene 1) with unknown biological functions. AAA1 is transcribed from the complementary
DNA strand to the opposite direction from GPRA (Figure 3).
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Figure 3. The exonic structures of GPRA and AAA1 genes around the conserved 133-kb haplotype block
(gray box). The two genes do not have overlapping exons, but instead are embedded inside each other’s
genes. There are two alternative 3' exons, 9a and 9b, in the GPRA gene, which encode full-length variants
of the receptor. The nonsynonymous polymorphism is located in exon 3. In the opposite DNA strand,
there is a previously uncharacterized AAA1 gene, which displays extensive alternative splicing. Eight
exons of the GPRA gene (E1 to E8) are shown for orientation. Modified from (I).
2. CHARACTERIZATION OF AAA1
2.1 Genomic structure of AAA1 variants (I)
The previously uncharacterized AAA1 gene is located in the complementary DNA strand
transcribed to the opposite direction from GPRA. The gene spans over 520 kb of the genomic
DNA (contig NT_000380, NT_007819) and is encoded by at least 18 exons (Figure 3). The
cDNA sequences of the AAA1 splice variants were assembled by using RT-PCR with primers
designed for predicted exons. Using cDNAs from human lung, kidney, testis and fetal liver as
templates, thirteen splice variants termed IA, IB, II, III, IVA, IVB and V-XIII were identified. All
variants share exon 6, but use alternative exons to encode the 5´ and 3’ ends of the transcript. In
most of the variants, the sequence flanking the putative ATG translation initiation site
(GCCATGC) contains the –3 purine, but not the +4 guanine residue, of the Kozak consensus
sequence surrounding the initiation codon of eukaryotic mRNA.
2.2 Expression pattern of AAA1 mRNA (I)
Northern  blot  analysis  of  a  multiple  tissue  expression  array  showed  that  AAA1  mRNA  is
expressed in several human tissues such as testis, brain, placenta, lung, heart, skeletal muscle,
kidney, liver, fetal liver and fetal lung. In situ hybridization revealed that AAA1 is expressed in
the epithelial cells in normal colon and lung tissues.
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2.3 AAA1 is a non-coding RNA gene (I)
All predicted AAA1 proteins sequences are small peptides (sizes from 34 aa to 74 aa) with no
significant  homology  to  any  known  modular  structures  or  motifs.  There  are  no  AAA1
homologues in the sequence databases of other species, e.g. mouse, rat, drosophila orthologues.
All AAA1 isoforms  contain  the  same  core  sequence
(AYVRRNAGRQFSHCNLHAHQFLVRRKQ) flanked by alternative amino- and
carboxyterminal tails. To test whether AAA1 encodes for any polypeptides, in vitro translation
experiments of AAA1 variants I and III in the presence of S35 -labeled methionine in the reaction
mixture were performed. Reaction products were analyzed by SDS-PAGE and autoradiography.
The commercial control DNA construct resulted in the synthesis of a 50-kDa polypeptide as
expected.  However,  neither  of  the  two  investigated  constructs  starting  from  the  common  short
open reading frame was translated into polypeptides. The finding suggested that AAA1 functions
as a non-coding RNA gene.
This was further confirmed in cell transfection experiments. The expression constructs
containing the open reading frame with C-terminal tag sequences for detection were negative for
immunofluorescence microscopy and Western blot analyses. In addition, cells transiently
transfected with HA-AAA1 fusion construct failed to produce recombinant protein detectable by
anti-HA antibodies.
Polyclonal antibodies were raised against the synthetic peptide YVRRNAGRQFSHC
containing the sequence included in the constant region of AAA1. The antibodies demonstrated
high affinity against the peptide and the constant region of AAA1 expressed as a GST fusion
protein. However, no signals were detected in either Western blots (spleen, skeletal muscle,
uterine muscle, colon muscle, colon epithelium, kidney, testis and prostate) or
immunohistochemistry (BEAS-2B, A549, HepG2, Ptks2, 293 and myoblast cell lines positive for
AAA1 mRNA).
3. CHARACTERIZATION OF GPRA AT mRNA LEVEL
3.1. Genomic structure and splice variants (I, II)
The full-length cDNA sequence of GPRA was assembled by using conventional RT-PCR with
primers designed for predicted exons. The alternatively spliced transcripts were further
determined by RACE-PCR using different sources of mRNA such as the human lung epithelial
carcinoma cell line NCI-H358 (ATCC) and commercially available cDNAs as templates. Nested
PCR amplification was utilized in producing full-length cDNAs of the various splice variants,
which have the same initiation sites but use alternative exons in encoding the 3’ end of the gene.
The GPRA gene spans 0.2 Mb of the genomic contig NT_000380 (NT_007819). The
open reading frame is distributed across 9 exons and the gene undertakes complex splicing events
(Figure 4). The longest GPRA transcripts express cDNAs of 1116 bp and 1134 bp producing
alternative  3'  exons  9a  and  9b  and  were  named GPRA-A and -B, respectively. The 133-kb
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segment spans from intron 2 to intron 5 of GPRA, but most of the strongly associated SNPs are
within  the  long  intron  2  comprising  93.8  kb  of  genomic  DNA.  However,  there  is  one
nonsynonymous polymorphism in the first extracellular loop of the receptor that replaces the Asn
107 with Ile.
The C variant is the shortest GPRA transcript including only the exons E1, E2 and E3a
encoding a 94 aa-peptide. Several additional novel splice variants termed D, E and F were
observed in the cloning process using PCR analysis with nested PCR specific for the A variant.
Variants GPRA-D -E and -F encode 158-, 136- and 305-aa peptides, respectively, which have a
deletion of either exon 3, 4 or both, respectively. The deletions result in an early stop codon for
GPRA-D and  -E variants, whereas GPRA-F shares  the  rest  of  the  reading  frame with GPRA-A.
GPRA-Bshort encoding a 366-aa peptide has an in-frame deletion of 33 bp (11 aa) at the beginning
of exon 3, while the rest of the downstream exons are the same as in GPRA-B (Figure 4).
Figure 4. Exon structure of the GPRA variants A-F. Black areas represent transmembrane regions in the
full-length receptor variants A and B. Gray areas indicate the alternative open reading frames producing
truncated proteins. Modified from (II).
3.2. Expression profiling by RT-PCR and Northern blot hybridization (I, III, IV)
According to RT-PCR analysis, different GPRA variants are expressed in several human tissues
including testis, brain, pituitary gland, placenta, lung, heart, thymus, and fetal heart. In Northern
blot analysis of a commercial eight-lane membrane, 1285-bp full-length GPRA-A cDNA probe
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detected a 2.4-kb transcript in spleen, thymus, prostate, testis, uterus, small intestine, colon and
peripheral blood leukocyte lanes. In addition, a 2.4-kb band was observed in the lung tissue and a
further 1.8 kb transcript in four tissues.
To  address  the  role  of  GPRA  in  inflammation,  mRNA  levels  of  the  mouse  ortholog  of
GPRA (Gpra) were investigated in a mouse model of OVA-induced lung inflammation with
additional  mold  exposure.  According  to  the  real-time  RT-PCR  analysis  (Taqman  assay),
metacholine induced hyperreactivity was associated with elevated pulmonary Gpra mRNA levels
in sensitized (n=7) mice when compared with unsensitized mice (n=8).
In order to identify the cell types expressing GPRA, mRNA expression of GPRA-A and -
B was further characterized in fractionated human blood cells using real-time RT-PCR with
SYBR Green chemistry. GPRA-A mRNA expression in peripheral blood mononuclear cells
(PBMCs) was similar to bronchial epithelial and bronchial SMCs. The expression of GPRA-B
mRNA was higher in PBMCs than in BEAS cells, but very weak in BSMCs. In fractionated
leukocytes, monocytes and eosinophils expressed both GPRA-A and GPRA-B mRNA, whereas
CD4+ T expressed mainly GPRA-B mRNA.
In order to examine the effects of monocyte and T-cell activation on GPRA expression,
PBMCs were stimulated with LPS or anti-CD3 and anti-CD28 antibodies, respectively. LPS
increased  GPRA-A  and  -B  mRNA  expression  16  and  28  h  after  challenge,  whereas  T-cell
activation with anti-CD3 and anti-CD28 antibodies decreased the expression 28 h after challenge.
Thus, GPRA expression in PBMCs correlates to the maturation of monocytes to macrophages.
The decreased expression of GPRA after T-cell activation may be a secondary effect produced by
induced cytokine production.
The nasal epithelium displays characteristics comparable to more distal airways and can
be used as a representative of pulmonary epithelium. GPRA mRNA expression was determined
in samples taken from the nasal respiratory epithelium of term and preterm infants, and healthy
adults using real-time PCR (Taqman assay). Strong signal (relative expression 353.3 ± 254.0,
mean  ±  SD)  was  observed  in  all  of  the  10  adult  samples,  whereas  the  relative  GPRA  mRNA
expression was weak (6.3 ± 3.8) in the 6 term infant and very weak or nonexistent (1.3 ± 1.7) in
the 7 preterm infant samples at the age of 1-4 h. No significant differences were observed in the
GPRA mRNA expression levels between the samples taken from the nasal epithelium at the age
of 1-4 h and 21-48 h of age. We also studied GPRA mRNA expression in 4 preterm infants with
BPD,  although  age-matched  control  samples  were  unavailable.  In  these  samples,  the  GPRA
expression was significantly higher (57.7 ± 32.4) than in the neonates sampled at the age of 1-4 h.
Taken together, these findings indicate that GPRA mRNA is expressed in leukocytes and
in several peripheral organs containing epithelial and SMCs. GPRA mRNA levels are increased
in a mouse model during inflammation.
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3.3. Expression profiling by in situ hybridization (II)
GPRA mRNA expression was studied in paraffine-embedded bronchial and colon sections as
well as tissue arrays containing 30 human tissues. Automated non-radioactive in situ
hybridization with a digoxigenin-labeled non-isoform-selective GPRA antisense probe resulted in
positive staining in epithelial cells of all tissues relevant to asthma and allergy including
bronchus, the gastrointestinal tract and skin. In addition to colon epithelium, also inflammatory
cells between the crypts expressed GPRA. In other lymphatic tissues, positive inflammatory cells
were detected in tonsils but not in the thymus gland. The glandular epithelia (e.g. in the salivary
gland and thymus) and submucosal epithelial cells of other peripherial tissues such as spleen,
kidney, pancreas, prostate, uterus and breast showed strong staining. Peripheral nerves, cerebral
cortex and cerebellum as well as the skeletal and the smooth muscle of various tissues were
negative. However, staining of frozen sections of bronchial tissue from asthmatic patients
resulted in strong mRNA expression also in the SMC layer suggesting a potential role for GPRA
in bronchial hyperresponsiveness. Staining with the sense probe resulted in no signal.
4. CHARACTERIZATION OF GPRA AT PROTEIN LEVEL
4.1. The predicted structure of GPRA (I)
According to the TMpred and PredictProtein softwares for protein prediction, the conserved
amino acid residues revealed similarities to the typical characteristics of the rhodopsin GPCRs.
These included two conserved Cys residues in exoloops 1 and 2 potentially forming a disulfide
bridge, the Asp-Arg-Tyr sequence (DRY motif) in the proximity of TM3, Asn-Pro-X-X-Tyr
motif in TM7, and a Cys residue in the C-terminal region. The putative N-glycosylation site in
Asn4 was predicted by the PredictProtein software. GPRA-A and -B encode 366 and 371 amino-
acid proteins with 7 TM domains containing mutually exclusive C-terminal intracellular tail
sequences (Figure 5).
The  closest  structural  homolog  is  the  vasopressin  receptor  V1a,  which  has  27  % amino
acid similarity to GPRA-A. Thus, GPRA belongs to the b-group of rhodopsin receptors (section
C: 3.1). A GPRA homologue exists in insects suggesting that an ancestor of this receptor was
present more than 700 million years ago. Because GPRA cannot be found in fish, it is possible
that its function is essential only for land-living species. In man, expressed sequence tags (ESTs)
for GPRA can be found both in central nervous system and peripheral tissues (Gloriam et al.
2005).
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Figure 5. Predicted protein structure of GPRA-A and -B. GPRA-A and -B encode 366 and 371 amino-
acid proteins with molecular weights of 42.7 and 43.1 kDa, respectively. The nonsynonymous Asn(107)Ile
polymorphism is located in the GPRA exon 3 encoding the first exoloop of the receptor. Modified from
Reinscheid et al. 2005.
4.2. Characterization of the GPRA antibodies (I, II, III)
Two different polyclonal antibodies detecting intracellular sequences against the two alternative
C-terminal tails (anti-GPRA-A and anti-GPRA-B) of GPRA were raised in rabbit by
immunization with the corresponding peptides conjugated to a KLH carrier protein. In order to
use parallel antibodies, additional polyclonal antibodies detecting the third cytoloop (anti-GPRA-
CL3) of the receptor and recognizing both GPRA-A and -B isoforms were raised in rabbit
according to the same protocol. To further obtain polyclonal antibodies against extracellular
epitopes of GPRA, a goat was immunized with a multiple antigen peptide containing the amino
terminus  (anti-GPRA-N)  of  GPRA and a  KKG core.  The  sera  were  screened  with  an  enzyme-
linked immunosorbent assay using the uncoupled peptides immobilized onto the nitrocellulose
filters as antigens. Positive antisera were purified with affinity chromatography using the
corresponding peptides as antigens in order to remove any cross-reacting IgG and other
contaminants. The antibodies were characterized by immunoblotting, peptide competition assays
and immunohistochemistry utilizing assays based on colour reaction and fluorescence.
To determine whether the purified antibodies detect their peptide epitopes, the antibodies
were characterized by immunoblotting of corresponding recombinant GPRA fragments produced
in Esterichia coli as fusion proteins (III). The peptides were expressed in pGEX 4T-3 GST fusion
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expression vector as GST fusion proteins except for the C-terminal tail of the A isoform, which
was expressed as a DHFR fusion protein. Epitope-specific signals were detected with no cross-
reactivity between the constructs or with the GST or DHFR or construct alone. For further
verification, use of molar excess of the free peptide as a competitor prevented the signal detection
in blocking experiments. Because the anti-GPRA-B and the anti-GPRA-N antibodies detected
also shorter GPRA variants produced as a result of protein degradation, full-length GST-
constructs were purified from the lysates with the aid of glutathione affinity chromatography.
Immunoblotting of the purified GST-constructs with the corresponding antibodies resulted in
detection of a single band as expected.
To show that the antibodies also recognize full-length receptor variants in
immunoblotting, myc-tagged GPRA-A and -B constructs were transiently expressed in COS-1
cells (II). Cells were harvested 48 h post-transfection, the crude membrane preparations were
isolated by ultracentrifugation and analyzed using anti-myc, anti-GPRA-A and anti-GPRA-B
antibodies. The anti-GPRA-A and anti-GPRA-B antibodies recognized the same recombinant
proteins as the anti-myc antibodies at about 35 to 50 kDa. Since the calculated molecular weights
of GPRA-A and -B are 42.7 and 43.1 kDa, respectively, the results indicate that there are no
extensive post-translational modifications in produced recombinant GPRA proteins.
The anti-GPRA antibodies were further studied in immunocytochemistry and
immunohistochemistry settings utilizing the parallel antibodies and knowledge from mRNA
expression studies. According to the results of these studies described in the following sections in
more detail,  anti-GPRA-N and anti-cytoloop-3 recognized the shared segments of the GPRA-A
and -B isoforms. However, the affinities of the GPRA-N antibodies were overall weaker when
compared with the cytoplasmic antibodies, which is typical for antibodies produced by
immunization against epitopes previously recognized by the immune system, i.e. extracellular
epitopes of the surface receptors.
4.3. Cellular localization of the splice variants (II)
In order to study the cellular localization of the different GPRA isoforms, COS-1 cells were
transiently transfected with N-terminally conjugated myc-tagged or C-terminally HA-tagged
pCMV-GPRA constructs. ELISA in both permeabilized and non-permeabilized cells as well as
fluorescence microscopy was used for detection of the myc-tagged GPRA-constructs. According
to the results, 71% of the produced GPRA-A and 52% of the GPRA-B were translocated to the
plasma membrane, while all the five shorter variants remained in the intracellular compartments
48 h post-transfection.
In order to further study the specificities of the antibodies in immunocytochemistry, COS-
1 cells grown on coverslips were transiently transfected with N-terminally conjugated myc-
tagged or C-terminally HA-tagged pCMV-GPRA constructs, permeabilized, and then incubated
with  anti-GPRA-A,  anti-GPRA-B,  or  anti-HA  antibodies  for  1  h.  Thereafter,  the  cells  were
incubated with fluorescent goat anti-rabbit IgG or goat anti-mouse IgG antibodies for 30 min.
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Samples were visualized with fluorescence microscopy. In consistence with the results obtained
from the  cell-based  ELISA assay,  anti-GPRA-A and -B antibodies  detected  the  receptor  on  the
plasma membrane  as  expected  also  from the  topology of  the  receptor.  However,  all  the  shorter
GPRA isoforms were maintained in the intracellular compartments as detected with anti-HA
antibodies.
In order to examine the effect of the truncated GPRA isoforms on the full-length GPRA-A or -B
translocation, COS-1 cells were co-transfected with myc-tagged GPRA-A or -B constructs and
truncated variant constructs with increasing concentrations. Subsequently, the relative amount of
the receptor on the plasma membrane was measured with the cell-based ELISA assay. According
to  the  results,  the  GPRA-A  and  GPRA-B  amount  on  the  plasma  membrane  remained  constant
despite of the presence or absence of other splice variants. To conclude, shorter GPRA isoforms
did  not  affect  translocation  of  GPRA-A  and  -B  and  the  role  of  the  various  GPRA  transcripts
remained unclear.
The expression of GPRA-A was further analyzed in AAA1 transfected COS-1 cells by
utilizing immunohistochemistry with fluorescent labels and immunoblotting analysis. According
to  the  results,  AAA1  did  not  affect  the  expression  of  GPRA  since  no  differences  in  GPRA
expression were observed between the transfected and non-transfected cell samples at 24 h or 48
h. The results were reproduced with conventional RT-PCR analysis, which showed no
differences in GPRA mRNA expression between AAA1 transfected and mock-transfected COS-1
cells 4 h and 24 h post-transfection.
4.4. Expression profiling by immunoblotting (II, III)
In immunoblotting experiments of human tissue lysates, detection with anti-GPRA-A antibodies
revealed one intensive polypeptide band corresponding to molecular weight of approximately 50
kDa  in  SMC  containing  tissues  such  as  uterine  muscle,  colon  muscle  and  prostate,  but  also  in
colon epithelium. Spleen and testis were negative for GPRA-A. With GPRA-B antibodies, a 50-
kDa polypeptide band was observed in all examined tissues, except in skeletal muscle. An
additional 39-kDa band was visible in testis. Detection with the anti-GPRA-CL3 antibodies
recognizing both isoforms A and B resulted in positive signals in overlapping polypeptide bands
confirming the results.
In addition, inflammatory cells expressed GPRA. Detection with both anti-GPRA-A and
GPRA-B antibodies revealed the 50-kDa polypeptide band in human sputum and PBMC
samples. The additional 60-kDa band observed in sputum samples after anti-GPRA-A detection
may represent a receptor form carrying differentially processed N-glycans, representing post-
translational modification that is typical for GPCRs. In PBMC lysates, the amount of both GPRA
isoforms was increased in LPS-treated PBMCs 48 h after challenge when compared with the
unstimulated samples. Quantification of the band intensities demonstrated that the increases in
GPRA-A and -B expression after LPS challenge were 1.4-fold and 1.6-fold, respectively,
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whereas T-cell activation with anti- CD3/28 antibodies did not modulate GPRA-A or -B
expression.
The calculated full-length molecular weights of the GPRA-A and GPRA-B proteins, 42.7
and 43.1, respectively, are in agreement with the observed results. For further verification of the
antibody specificities, omission of the primary antibodies and blocking experiments with 10-fold
molar excess of free peptide as a competitor were used to verify the correct polypeptide bands in
immunoblotting.
4.5. Expression profiling by immuhistochemistry (I-IV)
4.5.1 Normal human tissues (I, II)
The protein expression of GPRA-A and -B was characterized using paraffine-embedded sections
from bronchial, colon and skin tissue samples relevant to the pathogenesis of allergy and asthma.
In addition, commercial tissue arrays containing 30 normal adult human tissue samples were used
in further expression profiling of GPRA.
Immunostaining with the anti-GPRA-A antibodies resulted in weak immunoreactivity in
the epithelium of most tissues studied. SMCs in the bronchial and arterial walls were constantly
positive  for  GPRA-A  in  all  tissues  studied.  Immunostaining  with  the  anti-GPRA-B  antibodies
revealed ubiquitous protein expression in the glandular epithelia of bronchus, stomach, small
intestine, colon, uterus, esophagus, spleen, kidney, pancreas, prostate, and breast. In the distal
lung, both isoforms were present in alveolar macrophages and B isoform additionally in the
septal cells lining the alveolar epithelium. Interestingly, GPRA-A was expressed in the basal
surfaces of the colon epithelium and skin keratinocytes, whereas GPRA-B was expressed the
apical surfaces of colon and in the terminally differentiating skin keratinocytes. However, in
comparison to GPRA-B, the expression of GPRA-A was absent in some tissues such as stomach
and small intestine. Consistent with immunoblotting, neither of the isoforms showed
immunoreactivity in skeletal muscle.
The reliability of the results was further verified with the GPRA-N antibodies raised
against the N-terminus of GPRA. Staining with the GPRA-N antibodies was overall weaker than
with the GPRA-A and -B antibodies detecting intracellular epitopes of the receptor, but
consistently, the antibodies recognized GPRA isoforms in exactly overlapping positions, i.e., in
various  epithelial  cells  and  in  SMCs.  In  the  skin,  both  basal  and  apical  cells  of  the  stratified
epithelium were stained with the GPRA-N antibodies, whereas the middle layer was negative for
GPRA. An overall summary of GPRA-A and -B expression in different tissues is shown in Table
4, which also includes the expression of GPRA mRNA in the corresponding tissues.
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Table 4. An overall summary of GPRA-A and -B expression in different tissues as assessed by
immunohistochemistry and in situ hybridization. Anti-GPRA-N antibodies recognized epithelial and SMCs
in overlapping locations to GPRA-A and –B expression.
GPRA-A GPRA-B GPRA mRNA
LUNG SMC, macrophages SMC, macrophages, septal cells -
BRONCHUS SMC, epithelial cells Epithelial cells Epithelial cells
SKIN Basal cells Differentiated keratinocytes Keratinocytes ±
ESOPHAGUS Squamous epithelium,
muscularis mucosae, lymphatic
vessels
Arteria, lymphatic vessels Squamous epithelium
STOMACH SMC, neutrophils, glands Glandular epithelia Glandular epithelium
SMALL
INTESTINE
SMC, epithelial cells ± Epithelial cells Epithelial cells
COLON Basal cells, goblet cells Epithelial cells Epithelial cells,
inflammatory cells
HEART MUSCLE Arterioles, cardiomyocytes ± Cardiomyocytes ± Cardiomyocytes ±
SKELETAL
MUSCLE
- ± -
TONSIL - - +
SPLEEN - Arterial wall -
BONE MARROW Mature neutrophils + Immature neutrophils +, mature
neutrophils -
-
THYMUS GLAND - - Glandular epithelium
SALIVARY
GLAND
Mucous acini +, serous acini - Mucous acini +, serous acini - Glandular epithelium
ADRENAL
GLAND
Zona glomerulosa ± - +
THYROID
GLAND
- Epithelial cells Glandular epithelium
PARATHYROID
GLAND
Unrepresentative sample Unrepresentative sample ±
PITUITATORY
GLAND
Basophils +, acidophils ± - ±
PANCREAS The islet of Langerhans - Glandular epithelium
KIDNEY Epithelium ± Tubular epithelium ± Epithelium
BREAST Glandular epithelium Glandular epithelium -
OVARY - - -
UTERUS Glandular epithelium, SMC Glandular epithelium, SMC Glandular epithelium
PLACENTA Arteria - ±
PROSTATE SMC, epithelium SMC, epithium - Epithelium
TESTIS - - -
OMENTUM - - -
CERVIX Squamous epithelium ± Squamous epithelium ± -
PERIPHERAL
NERVE
- ± -
CEREBRAL
CORTEX
- - -
CEREBELLUM - - -
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4.5.2 Pulmonary expression of GPRA in asthma, RDS and BPD (I, IV)
In order to clarify the role of GPRA expression in the pathogenesis of asthma, GPRA-A and -B
immunoreactivity was examined in 8 paraffin-embedded bronchial biopsies from asthmatic
patients  and  compared  with  the  expression  of  10  control  samples  from non-asthmatic  subjects.
The GPRA-A expression was similar in asthmatic and nonasthmatic subjects with the strongest
expression in the bronchial SMCs and additional expression in the epithelial cells. In healthy
subjects,  GPRA-B was  expressed  in  the  epithelial  cells  but  not  in  SMCs of  the  bronchial  wall.
Strikingly, GPRA-B was upregulated in the SMCs of asthmatic airways in each of the studied
samples. Because the genetic risk effects of the GPRA haplotypes are estimated to account for
over half of the Finnish asthma patients as opposed to approximately one third of the healthy
controls, the clear-cut upregulation of GPRA-B in asthmatic patients is unlikely to be caused by a
genetic drift. The findings, however, indicate that GPRA may be involved in the development or
maintenance of BHR in asthmatic patients. The GPRA immunoreactivity in leukocytes suggested
a further role for the receptor in inflammation.
To further explore the link between GPRA expression and BHR, GPRA-A and -B
immunoreactivity was analyzed in paraffin-embedded autopsy samples of preterm infants with
RDS and BPD showing clinical features of increased SMC contractility, and compared with
midterm fetuses and term infants. In term infants who lived up to 24 h and died of
extrapulmonary  causes,  GPRA-A  and  -B  expression  was  weak  but  similar  to  the  healthy  adult
controls.  Neither  GPRA-A  nor  GPRA-B  was  expressed  in  midterm  fetal  lung.  Similarly  to
asthma, GPRA-B expression was upregulated in the SMCs of the large bronchi in RDS and BPD.
Also the epithelial expression of GPRA-B in bronchi was slightly more intensive in RDS and
BPD than in the full-term controls, whereas GPRA-A immunoreactivity did not differ from the
staining of the full-term controls. These observations suggest that GPRA could contribute to the
susceptibility to BHR.
4.5.3 Mouse model (III)
Paraffine-embedded lung tissue samples of classical OVA-induced murine model of asthma were
analyzed by immunohistochemistry to examine the protein expression of GPRA during
inflammation. Public mouse genome databases do not include the sequence for the B isoform and
thus, only the anti-GPRA-A specific antibodies were utilized. However, the specificity of the
immunostaining could be further verified with the GPRA-CL3 antibodies detecting intracellular
third cytoloop common to all receptor isotypes. The corresponding murine epitope is identical to
the human sequence except for the first amino acid.
In the lung tissue of naïve and unsensitized but OVA-challenged mice, GPRA-A was
expressed  in  the  epithelial  cells  of  the  bronchioles  as  expected  from  the  human  studies.  In  the
OVA-challenged mice without sensitization, nonexistent to moderate immunostaining was also
observed in alveolar macrophages. In the OVA-sensitized and -challenged mice, GPRA-A
expression was decreased in the epithelial cells of the bronchioles, whereas the expression was
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increased in macrophages when compared to the naïve and OVA-challenged groups without
sensitization. The staining of the corresponding sections with the GPRA-A preimmune sera did
not result in any immunoreactivity. Staining of the corresponding sections with the GPRA-CL3
antibodies resulted in identical immunoreactivity in overlapping locations to the anti-GPRA-A
stainings.
In  order  to  further  confirm  the  GPRA  expressing  cell  types,  BAL  samples  from  the
corresponding study groups were stained. In the BAL fluid of naïve control mice, GPRA
expression in the alveolar macrophages varied between nonexistent to very low. Moderate GPRA
expression was observed in macrophages of OVA-challenged mice without sensitization. In the
asthma model of OVA-sensitized and -challenged mice, GPRA staining in macrophages varied
from mild to strong. Positive GPRA staining was also detected in eosinophils. These results
confirmed the findings indicating upregulated GPRA expression in tissue infiltrated macrophages
upon allergen challenge.
5. FUNCTIONAL STUDIES OF GPRA (II, III)
5.1. Expression of neuropeptide S, an endogenous ligand for GPRA (II, III)
We did not succeed in raising polyclonal antibodies against the polypeptide and therefore, NPS
expression could only be assessed at mRNA level. According to the results obtained with
quantitative real-time RT-PCR, NPS mRNA expression in blood cells resembled the expression
profile of GPRA. Similarly to GPRA, the expression of NPS mRNA was upregulated in PBMCs
16 and 28 h after LPS stimulation and T-cell activation with anti-CD3 and anti-CD28 antibodies
decreased NPS expression 28 h after challenge. Furthermore, in situ hybridization of bronchial
and colon sections revealed that NPS mRNA is expressed in the epithelia in overlapping
locations to the cognate receptor GPRA. These findings support the idea that NPS may activate
GPRA by an autocrine or paracrine mechanism.
5.2. GPRA-A overexpressing cell line (II, III)
Human kidney epithelial cell line 293H did not express endogenous GPRA-A, as determined by
real-time RT-PCR, and was used as a host in constructing a lineage stably overexpressing GPRA-
A. After transfection with the corresponding GPRA-A DNA constructs, the clones were
identified by RT-PCR and immunoblotting analyses. Three GPRA-A positive clones, two GPRA-
A negative clones and the parental 293H cell line were selected for further experiments.
Nonradioactive GTP-binding assay  was  utilized  in  order  to  validate  the  signal
transduction activities of the receptor. After 1 µM NPS challenge, GPRA-A positive cell clones
displayed a 2-3 -fold increase in GTP-binding activity when compared with the GPRA-A
negative cell clones. For measurements of cytoplasmic Ca2+ levels, the cells were labeled with
Fluo-3 AM as an indicator. Ten to fifteen seconds after injection, NPS (1 µM) increased
fluorescence levels indicating Ca2+ release to the cytoplasm of the GPRA-A overexpressing cells.
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No change in Ca2+ levels was detected in parental 293H cells. In an ELISA-based assay, 20 min
stimulation  with  1  µM  NPS  resulted  in  a  36-40  %  increase  in  basal  cAMP  levels  in  GPRA-A
overexpressing cells but not in parental 293H cells. These findings indicate that NPS is able to
activate its cognate receptor GPRA by increasing intracellular Ca2+ and cAMP accumulation.
To examine the effects of GPRA-A activation on cell growth, GPRA-A positive and
negative cell clones were treated with NPS for 3 d, and the relative cell numbers were determined
using the colorimetric proliferation assay.  According  to  the  results,  the  GPRA-A  positive cells
grew slower than the GPRA-A negative cells. The GPRA-A dependent cell growth was further
inhibited by 1 µM NPS treatment (p < 0.05).
In consistence with the proliferation assay, cell counting at different time points indicated that the
stably GPRA-A overexpressing cells grew slower than the negative control cells. After 2 and 4 d
of culture, GPRA-A positive cells had grown 18% (p < 0.01) and 14% (p < 0.05) slower than the
GPRA-A negative control cells, respectively. Addition of puromycin used as a selection marker
for the construct intake had no influence on cell growth.
5.3. Macrophage cell line (III)
RT-PCR and immunohistochemistry experiments were used to demonstrate that murine
macrophage cell line RAW 264.7 express GPRA at mRNA and protein levels, and was used as a
model for GPRA-mediated macrophage functions. In phagocytosis assay, 1h prestimulation with
NPS resulted in a dose-dependent and up to 10.8 -fold increase in cellular intake of fluorescein-
labelled Esterichia coli (p<0.001) during 2 h incubation. When visualised with fluorescence
microscopy, the increase was apparent in the intracellular compartments, whereas the nuclei of
the cells did not emit any fluorescence.
In order to identify the specific signalling pathways involved in the NPS-mediated
phagocytosis, specific inhibitors for intracellular Ca2+, protein kinase C and protein kinase A
were used. Incubation with each of the inhibitors resulted in a decrease in NPS-mediated
phagocytosis when compared to the cells treated with NPS alone. The most effective inhibition
was obtained with bisindolylmaleimide I (PKC inhibitor), which decreased the NPS -mediated
phagocytosis approximately 70 % (p < 0.05). Use of the inhibitors did not decrease phagocytosis
in cells not treated with NPS indicating that NPS-stimulated phagocytosis was individually
dependent on all pathways involving intracellular Ca2+, protein kinase C and cAMP.
Because directed cellular movement is characterized by a dynamic control of attachment
and detachment of the cell surface adhesive receptors with their extracellular matrix ligands, we
studied whether NPS modulates cell adhesion in RAW 264.7 cells. Maximal activation of the
GPRA-A overexpressing cells and increased phagocytosis of the RAW cells was obtained with 1
mM NPS concentration and hence, it was selected for the cell adhesion and migration studies.
Cells were preincubated in the presence or absence of NPS for 30 min and seeded onto
fibronectin, collagen type I or poly-L lysine coated wells for 50 min. Cell adhesion on
immobilized fibronectin was slightly but significantly (p = 0.013) decreased in the samples with
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NPS preincubation. Poly-L-lysine was used as a matrix to support unspecific non-integrin -
mediated adhesion, and did not affect NPS-mediated cell adhesion. For further demonstration of
the importance of the immobilized matrix, collagen type I did not support adhesion of RAW
264.7 cells (data not shown). Because the observation of fibronectin binding to integrins a4b1
and a5b1 in hematopoietic cell-matrix adhesive interactions is well established (e.g. Gu et al.
2003), our results suggest that NPS-dependent cell detachment may be mediated by integrins.
In a quantitative fluorescence-based cell migration assay, a 2-fold increase (p = 0.007) in
RAW  cell  migration  was  detected  2  h  after  NPS  stimulation.  The  results  were  confirmed  in
another assay, where random migration of confluent RAW cells was measured 24 h after NPS
stimulation. According to visual analysis, the migration of the cells was increased onto the
denuded culture dish in the presence of NPS when compared to the untreated control cells.
6. GPRA AS A GENETIC REGULATOR OF RESPIRATORY DISTRESS SYNDROME
(IV)
To study  whether  GPRA associates  with  RDS or  BPD,  the  seven  haplotype  tagging  SNPs  in  a
70.7-kb interval of the GPRA gene intron 2 were genotyped in a case-control setting of Finnish
infants (Table 5). Because of the lack of unamplified genomic DNA from all of the subjects,
DNA was extracted from dried blood spots, amplified with the improved primer preamplification
(I-PEP-L) method and genotyped using the Sequenom platform (Hannelius et al. 2005, Sun et al.
2005).  However,  the  amount  of  DNA  was  too  low  for  proper  amplification  in  some  of  the
samples and therefore, these were excluded from further analysis decreasing the sample
population from of 521 to 435 subjects.
Three age-matched case-control comparisons were made. The first comparison was
performed in very preterm infants with gestational age (GA) < 32 weeks with (n = 82) or without
RDS (n = 42), and the second in near-term infants born at 32?GA<35 weeks with (n = 43) or
without RDS (n = 87). In the third analysis, very preterm infants with BPD (n = 37) were
separately compared with GA-matched controls with or without RDS.
In the second group consisting of near-term infants, haplotype H1 was underrepresented
(OR 0.5; 95% CI 0.3-0.8; P = 0.01), whereas haplotype H4/H5 was overrepresented in the RDS
group (OR 2.6; 95% CI 1.2-5.5; P = 0.01). Although the seven SNPs included in this study were
selected on the basis of tagging the previously identified haplotypes H1-H8, we also examined
possible associations for the individual SNPs with the outcomes mentioned above. At the allelic
level, genotyping of each SNP except for the rs323917 tagging H7 resulted in significant
differences in the allele frequences between cases and controls in near-term infants. The pairwise
linkage disequilibrium values (D´) between the markers and the single-marker allele frequencies
are presented in Figure 6. Corresponding associations were not found in the group of very
preterm infants with RDS or BPD.
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Figure 6. A Haploview illustration of the 70-kb haplotype block (Gabriel et. al 2002) in the GPRA gene.
The numbers in each box correspond to the pair-wise linkage disequilibrium coefficient D' between
respective SNPs. D' in the unmarked boxes corresponds to total linkage disequilibrium. All the samples
were analyzed together and the numbers on the right represent haplotype frequencies within the whole
study population. The SNPs are ordered according to their position in the gene (Figure 3, Table 5). The
SNP 546333 tagging haplotype H4 was excluded from the studies because of low success rate, which
made it virtually impossible to unambiguously distinguish between homozygotes and heterozygotes. In
order to avoid bias in the allele/genotype distributions, we analyzed the haplotypes H4 and H5 as one
(H4/H5).
Table 5. Single nucleotide polymorphisms (SNPs) within the 133-bp region defining the GPRA
haplotypes H1-H8. In addition, the SNP rs324981 tagging for the Asn/Ile change in the GPRA exon 3 is
presented. The asthma risk haplotypes in the Finnish studies are shown in gray.
515224 522363 529556 546333 555608 563704 585883 591694
SNP rs323917 rs323922 rs324377 rs324384 rs324396 rs740347 rs324981
C/G G/C A/C G/A T/C C/T G/C Asn/Ile
(A/T)
H1 C G C G C T G A
H2 C C A G T C G T
H3 C G C G C C G A
H4 C C A A T C C T
H5 C C A G T C C A/T
H6 C G C G T C G T
H7 G C A G T C G T
H8 C G A G T C G
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G. DISCUSSION
The starting point of the current study was the positional cloning of a novel asthma susceptibility
locus on chromosome 7p14.3 and the identification of two potential genes within it. In this thesis
work, we continued the work performed in our group and characterized both genes, GPRA and
AAA1 to some extent, focusing our interest ultimately to the expression and functions of GPRA.
1. GPRA expression and functions in peripheral tissues
A large fraction of the current data is based on the use of polyclonal antibodies, which have
certain limitations and have to be carefully characterized before any definite conclusions can be
drawn. The lack of knowledge from previous studies further impedes the interpretation of the
data concerning the expression of a novel gene. Hence, the specificities of the anti-GPRA-A and -
B antibodies were determined with special causion by using several parallel GPRA antibodies
and commercial antibodies against different protein labels in several experimental techniques. In
addition, the results were compared with the data obtained from the mRNA expression studies.
All the anti-GPRA antibodies detected their bacterial recombinant peptides with
extremely high affinity in immunoblotting. The anti-GPRA-A and -B antibodies also recognized
the same full-length receptor variants in immunoblotting and immunocytochemistry as the
commercial antibodies against their peptide labels conjugated to the transfected GPRA
constructs. As it seemed that the antibodies were specific for their intracellular epitopes, we
utilized them in immunohistochemistry using either preimmune sera or species-matched IgG
fractions as negative controls. The parallel GPRA antibodies against distinct epitopes of the
receptor were utilized in confirming the results. Staining with the anti-GPRA-A, -B and -N
antibodies resulted in staining of various epithelial surfaces as well as smooth muscle. Hence, we
further demonstrated that peptide blocking eliminates the GPRA-A and -B immunoreactivity
from the skin keratinocytes and subepithelial SMCs (P. Holopainen, unpublished results). For
further confirmation of these results, use of several parallel techniques yielded compatible results.
In agreement with immunohistochemistry, immunoblotting of human tissue lysates (including
colon muscle and epithelium) with the anti-GPRA-B antibodies revealed polypeptide bands in
tissues rich in epithelia, whereas detection with the anti-GPRA-A yielded chemiluminescence
especially in the SMC containing tissues. For further verification, detection with the anti-
cytoloop-3 antibodies recognizing both isoforms A and B resulted in positive signals in
overlapping polypeptide bands and peptide blocking experiments removed the corresponding
bands in immunoblotting.
Data obtained from GPRA mRNA expression studies were in line with the protein
expression studies. Northern blotting analysis of several human tissues including lung, colon,
small intestine and peripheral blood leukocytes resulted in detection of transcripts at correct
molecular sizes. The nasal respiratory epithelium was used as a representative of pulmonary
epithelium and displayed strong GPRA mRNA expression with quantitative real-time RT-PCR of
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adult samples. Most importantly, characterization of GPRA mRNA expression with in situ
hybidization yielded similar results to immunohistochemistry in overlapping locations to protein
expression (Table 4). Most of the discrepancies between the results of the two methods are likely
to originate from the dissimilar morphology between the small samples used in commercial tissue
array stainings. Although the smooth muscle staining of GPRA-A was weakened and even
removed upon peptide blocking experiments, the absence of GPRA mRNA expression in the in
situ hybridization experiments still stays a major concern. A biological explanation for this
discrepancy could involve the slower growth-rate of the SMCs in comparison to the rapidly
regenerating epithelial cells, which could hamper the detection of smooth muscle -derived GPRA
mRNA in the assay. Nevertheless, we could confirm the upregulated GPRA-B protein expression
in SMCs of asthmatic patients at mRNA level.
These observations strongly argue that the GPRA antibodies recognize their correct
epitopes,  but  do  not  totally  exclude  the  possibility  they  could  detect  some  other  cross-reacting
polypeptides, especially in techniques such as immunohistochemistry, in which the results are not
easy to validate. This concerns especially the tissues of murine origin, although the homology
between mouse and human GPRA-A epitopes was 79 % and the dissimilar amino acids possessed
structural similarity. The polypeptides used for immunization contained no homology to any
other known proteins than GPRA, but the cross-reactivity to epitopes not included in the current
databases remains to be shown.
2. GPRA as a genetic marker of asthma
After our original association study of GPRA with asthma-related traits, there have been four
replication studies, which have provided solid evidence for GPRA as a susceptibility gene for
asthma and related traits. The first report did not find any associations with asthma, atopy, or
total serum IgE values in a study conducted in a Korean case-control cohort consisting of over
800 subjects (Shin et al. 2004). However, instead of a complete haplotype analysis, only one SNP
(rs323922) was genotyped. Further studies have suggested that rs323922 may not be the best
choice for a haplotype tagging SNP. As shown, the genetic background among white and Asian
populations as well as the different environment may result in different haplotypes.
In  the  second  study, GPRA polymorphisms  were  shown  to  associate  with  asthma,
rhinoconjunctivitis, and sensitization in two cohorts of European origin consisting of 3,113 and
800 children (Melen et al. 2005). The associated haplotypes could be allocated into risk (H5/H6)
and nonrisk (H1/H3) groups. Especially the pattern of protective haplotypes was supported by
allelic associations of two SNPs: rs324384 tagging the haplotypes H1/H3 and rs324396 tagging
the haplotype H1. In parallelel with Melén and coworkers, Kormann and coworkers provided
evidence  that  in  addition  to  asthma  and  elevated  serum  IgE,  the  polymorphisms  were  also
associated with BHR in a German study cohort (Kormann et al. 2005). The SNP546333
(Hopo546333) tagging the haplotype H4 increased the risk for asthma (odds ratio 1.40), and this
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association was even more evident when concomitant asthma and BHR were present (odds ratio
2.38).
In  the  most  recent  study,  the  association  of GPRA polymorphisms with airway
responsiveness to metacholine was studied in a Chinese population isolate including 451 cases
and 232 controls (Feng et al. 2006). The observed GPRA haplotype pattern was less polymorphic
than in white populations and only three common haplotypes with no associations with asthma
were identified. However, the AA homozygote of the SNP rs324981 flanking the
nonsynonymous polymorphism in the GPRA exon 3 was shown to be protective against  airway
responsiveness to metacholine. Moreover, each additional copy of allele A reduced the risk by 21
%. An additional intronic SNP rs324987 in linkage disequilibrium with the SNP rs324981 also
showed a similar association pattern.
In the European studies, the non-coding intronic SNPs within the 70-kb haplotype block
accounted for the strongest associations. The nonsynonymous Asn(107)Ile polymorphism was
located in the middle of this region, but didn´t initially appear as a haplotype tagging SNP.
However, looking back to the sequencing data within the Finnish patients (Laitinen 2004, Table
5), Asn107Ile divides the observed risk and non-risk/protective haplotypes in the European
studies into two separate groups: The individuals with the risk haplotypes carry the Ile107 variant
whereas the subjects with the observed non-risk/protective haplotypes carry the Asn107 variant of
the receptor (Figure 7).
Figure 7. Phylogenetic tree of the seven GPRA haplotypes with frequences over 5 % in the studied
European populations (Laitinen et al. 2004, Melen et al. 2005).
These association studies introduce GPRA as the best candidate gene and a drug target for
asthma identified by genetic means so far. However, several important questions can be raised.
Most importantly, how exactly do the polymorphisms in the GPRA gene link to the mechanisms
involved in the complex pathogenesis of asthma, such as epithelial inflammation, immune
mechanisms and BHR?
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Reinscheid and co-authors provided one straightforward explanation. They reported that
the SNP rs324981 giving rise to the Asn(107)Ile polymorphism resulted in a gain-of-function
characterized by an increase in agonist potency without changing binding affinity to NPS in a
GPRA overexpressing epithelial cell line (Reinscheid et al. 2005). On the basis of our results in
asthmatic biopsies, the authors suggested that GPRA Ile107 variant could transmit enhanced
contractile response in airway SMCs requiring lower agonist concentrations in asthmatic
condition. Similar findings of polymorphism functions have been reported with the
nonsynonymous  SNP  in  the  CysLTR  and  with  the  synonymous  SNP  in  the  PG  receptor  genes
(section C: 3.3.1, Pillai et al. 2004, Oguma et al. 2004). Reinscheid and collegues also showed
that NPS induced dose-dependent proliferation of Colo205 human colon cancer cells
endogenously expressing GPRA and thus, suggested that the NPS-mediated proliferation could
play a role in the remodelling events of SMCs in the developing asthma.
Further evidence of the importance of the Asn(107)Ile polymorphism was provided by
Bernier and co-authors, who showed that residues 5-13 within the NPS peptide regulate GPRA
activation (Bernier et al. 2006). The inhibitory effect of this regulatory region was absent in the
Ile107 variant of the receptor suggesting an interaction between the NPS residues 5-13 and the
receptor residue 107. The Ile107 variant of the receptor also showed increased cell-surface
expression compared with the more common receptor variant, which could explain the increased
signalling observed by Reinscheid et al.
3. GPRA as a marker of inflammatory diseases and respiratory distress syndrome
Gupte and co-authors showed that GPRA was expressed only in the hypothalamus and retina
(Gupte et al. 2004). They suggested a role for the receptor in light detection and regulation of
circadian rhythm, because the retinitis pigmentosa 9 (RP9) locus maps to the 7p14-15 locus.
However, no association studies exist so far. According to our unpublished results, the anti-
GPRA antibodies detect immunostaining in retina of man and murine origin consistent with the
results of Gupte and co-authors. In addition to skin, gastrointestinal tract and lungs, also the outer
parts of the eye are prone to allergic responses and thus, GPRA expression in the eye is in
agreement with the theory of the receptor as a common mediator of allergic responses.
In addition to epithelial  tissues lining outer and internal body surfaces that are normally
populated with commensal non-dangerous microbes, we also showed that GPRA was expressed
in macrophages. Just recently, the expression of GPRA in blood monocytes was confirmed using
fluorescence activated cell sorter and the GPRA antibodies developed in our studies (Anna
James, unpublished observations). According to our functional studies, the GPRA/NPS pathway
appears to be involved in the complex signaling events of phagocytosis suggesting a function for
GPRA in the innate immune system. This hypothesis is also supported by our genetic findings
reporting association of GPRA with RDS, which has previously shown significant associations
with genetic variants of the surfactant protein (SP) -A, -B, -C and -D genes (Hallman et al. 2002,
Lahti et al. 2004, Nogee et al. 2004). SP-A binds to carbohydrate moieties on the surfaces of
67
viruses, bacteria and fungi and thus facilitates microbial aggregation and phagocytosis and killing
of certain micro-organisms by alveolar macrophages (Pikaar et al. 1995, Eggleton 1999). In SP-D
deficient (SP-D -/-) mice, SP-D is critical for the modulation of early stages of allergic
inflammation in vivo. Allergen-induced Toll-like receptor 4 expression was increased in wild
type  mice,  but  not  in  SP-D -/-  mice  (Schaub et  al.  2004).  Thus,  the  expression  pattern  and  the
macrophage functions of the NPS/GPRA pathway show overlapping role with SP-A and SP-D in
the first-line defence of the innate immunity (Crouch et al. 2000, Hohlfeld et al. 2002). Further
evidence for these functions is supported by the results obtained from a recent microarray
experiment carried out in our group (Vendelin et al., manuscript submitted). When GPRA-A
overexpressing epithelial cells were stimulated with NPS and compared with the parental cell line
not expressing GPRA-A, immune and defence responses to pest, pathogens and parasites were
among the several upregulated gene pathways. The studies also supported our functional studies
by  showing  that  regulation  of  cell  proliferation,  chemotaxis  and  response  to  wounding  were
among the major upregulated pathways.
Interestingly, the newly cloned positional candidate genes for asthma have shown
associations  not  only  with  AD,  but  also  with  IBD and MS (Noguchi  et  al.  2005,  Nicolae  et  al.
2005). The immunomodulatory functions together with the expression pattern in the skin and
throughout the digestive tract introduce the GPRA gene as a prime candidate for autoimmune
diseases and allergic diseases other than asthma as well (Cookson 2004). However, no
association of the GPRA polymorphisms with AD was found in a study conducted by Veal and
collegues (Veal et al. 2004). This underlines the different etiopathogenesis of asthma and AD and
may highlight the importance of inhaled allergens in the development of asthma. In genome wide
scans, the 7p14 locus has shown significant linkages to MS (Sawcer et al. 1996) and to IBD in
several studies (Satsangi et al. 1996, Cho et al. 1998, Rioux et al. 2000) as well as in a recent
meta-analysis of genome scans for IBD (van Heel et al. 2004) suggesting that these diseases may
share predisposing elements with asthma. NOD1 is a pattern recognition receptor located on
chromosome 7p within 5 Mb of the reported peak of genetic linkage. An intronic insertion
deletion polymorphism in the NOD1 gene was associated with asthma and high IgE (Hysi et al.
2005), but also to IBD (McGovern et al. 2005). NOD1 polymorphisms are also associated with
atopic eczema and related phenotypes indicating that intracellular recognition of specific bacterial
products may affect the presence of these diseases (Weidinger et al. 2005). However, this gene is
unlikely to explain the observed linkage in the Finnish genome scan. Thus far, there are no
publications reporting association of GPRA with  allergic  or  autoimmune  diseases  of  the
gastrointestinal tract. Nevertheless, a forthcoming report indicates a strong association of GPRA
haplotypes  with  IBD  (Mauro  D’Amato,  manuscript  submitted).  The  report  also  confirms  the
expression of GPRA in the gut by showing mRNA expression results from several biopsies
obtained from mucosal surfaces with or without inflammation.
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4. GPRA as a regulator of anxiety and sleep
We initially cloned the human GPRA gene from commercial cDNA samples originated from
brain. During our studies, we also observed strong GPRA mRNA expression in the mouse
hypothalamus and pituitary gland. Xu and co-workers also showed that GPRA is widely
expressed in the brain with high levels in the hypothalamus (Xu et al. 2004). Unfortunately, the
positive brain areas were not among the small tissue sample used in our microarray stainings.
Additionally, Xu and co-workers showed that central administration of NPS promoted behavioral
arousal and suppressed all stages of sleep in rodents. Furthermore, the peptide produced
anxiolytic-like effects in experiments measuring behavioral responses to novelty or stress in
rodents.
How could these events then be linked to inflammation and asthma? The first evidence is
obtained from epidemiological studies. In a large study, psychobehavioral variables in early life,
such as attention problems and overactivity, paved the way for the development of late-onset
wheeze, and could even be linked to its development (Calam et al. 2005). Similarly, panic
disorder and early childhood anxiety were suggested to predict subsequent asthma in adults
(Hasler et al. 2005). The careful analyses have excluded the possibility of mere cause and effect
phenomenon in these association studies. Nocturnal symptoms and overnight decrease in lung
function are typical indications of clinical asthma and 75% of patients suffer from the symptoms
at least once per week. Of those, approximately 40% experience cough and dyspnea on a nightly
basis (Sutherland 2005). As a second body of evidence, increasing data indicates that these
symptoms are related to circadian variations in airway inflammation and measurable physiologic
outcomes, such as AHR.
Many important effector molecules in asthma are involved in sleep regulation (Majde and
Krueger 2005). These include cytokines, nitric oxide, PGD2 (Hayaishi 2002), adenosine and
numerous neuropeptides such as neuropeptide Y, whose receptor shares the same branch with
GPRA in the phylogenetic tree of GPCRs. In addition to its functions in the CNS, neuropeptide Y
also mediates immune functions in various inflammatory cells. On the other hand, the
proinflammatory cytokine IL-1? is one of the most neurologically active molecules known.
Furthermore, one of the most widely recognized effects of adenosine is its ability to control CNS
functions in both physiological and pathophysiological conditions including asthma. In basal
state, adenosine concentration in the extracellular space is very low, but increases after
metabolically stressful conditions. Modest increases in extracellular adenosine concentrations
activate specific adenosine GPCRs resulting in the modulation of many brain functions, most
notably the regulation of sleep and arousal, locomotion, anxiety, cognition and memory (Haskó et
al. 2005).
Microbial factors such as bacteria, LPS, and viral and synthetic double-stranded RNA,
increase non–rapid-eye-movement sleep (NREM) and reduce REM in rabbits and induce IL-1,
tumor necrosis factor ?, IL-6 and other cytokines (Majde and Krueger 2005). According to the
hypothesis, the sequence of events starts with microbial invasion into the peripherial tissues,
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phagocytosis, and release of pathogen-associated molecular patterns into the tissue. They are
detected by Toll-like receptors or scavenger receptors, such as MARCO (macrophage receptor
with collagenous structure) (Elomaa et al. 1995, Arredouani et al. 2005), inducing local
epithelium and phagocytes. These cells produce proinflammatory cytokine mediators to act on
brain, where cytokines are able to induce other proinflammatory cytokines in the hypothalamus
and elsewhere.  As  a  result,  this  induces  NREM sleep  and  release  of  mediators  that  may either
dampen or induce the inflammatory events. Thus, the immunomodulatory effects of GPRA in the
peripherial tissues observed in this work may not be contradictory to the results observed within
the neuroscience community. It remains to be shown whether the functions of GPRA in
peripherial tissues (and especially in SMC) are actually neurally mediated indirect actions.
5. Future challenges
There are several future challenges and important questions to be answered. What are the
functions and the differences between GPRA-A and -B isoforms in various structural and
inflammatory  cells?  What  are  the  consequences  of  alternative  splicing  and  dysregulation  of
isoform balance in asthma, and how exactly do they relate to the polymorphisms in the 7p14-p15
locus? At the time of writing, the findings quite strongly argue for an important role of the
Asn107Ile polymorphism in the associations observed between GPRA and asthma-related traits.
The findings among the Chinese patients do not only further support the hypothesis of the
categorization of GPRA risk and non-risk/protective haplotypes, but also suggest direct
involvement of the nonsynonymous polymorphism in the signal transduction of the receptor as a
potential disease causing mechanism. The nonsynonymous SNP can also be found in non-
asthmatic subjects and therefore, environmental factors may somehow trigger the hazardous
effects of this SNP. Nevertheless, this interaction does not probably account for all of the genetic
interactions. Additional genetic mechanisms of how the polymorphisms could affect the disease
mechanisms include the regulation of allele-dependent splicing and/or the expression of the A
and B isoforms. Future knock-down experiments with RNAi techniques and the development of
GPRA antagonists will finally help in validating the functions of the various GPRA isoforms.
Studies in GPRA deficient mice are on their way and will be helpful in clarifying the function and
the biological role of GPRA. The replication and association studies of GPRA with other diseases
as well as careful characterization of the GPRA functions in the various cells types will
strengthen the understanding of the genetic mechanisms modifying the individual disease risk.
The advanced techniques in the field of genetic analyses can be utilized in order to examine the
interaction of GPRA with  other  positional  candidate  genes  affecting  asthma  susceptibility.  The
effects of GPRA brain functions to asthmatic responses as well as the role of NPS as a possible
mediator of these outcomes remain to be determined in future studies.
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H. SUMMARY AND CONCLUSIONS
We have identified a novel asthma susceptibility gene (GPRA, G Protein coupled Receptor for
Asthma susceptibility, alias GPR154, also known as neuropeptide S receptor) on chromosome
7p14.3 by means of positional cloning. GPRA haplotypes were associated with an increased risk
of asthma related traits both in Finnish and Canadian cohorts. Asthma and respiratory distress
syndrome (RDS) may share the same susceptibility and protective GPRA haplotypes for the
individual risk of the disease.
GPRA is expressed in relevant tissues and immune cells regarding to asthma and allergic
diseases. The universal expression pattern in the epithelial cells and the upregulated protein levels
of  GPRA in  the  bronchial  smooth  muscle  cells  both  in  asthma and  in  severe  RDS turns GPRA
into a potent candidate gene for other respiratory diseases as well and suggest a role for the
receptor in bronchial hyperresponsiveness.
NPS, an endogenous agonist for GPRA, co-localizes with GPRA in the immune cells and in the
bronchial epithelium. In a mouse macrophage cell line, NPS stimulates Gas and Gaq -dependent
phagocytosis of Esterichia coli. Combined with the results obtained from a mouse model of
asthma, the findings suggest GPRA to participate in the removal of inhaled particles after antigen
challenge.
In conclusion, the results suggest that in addition to the polymorphisms in the GPRA gene that
influence on asthma susceptibility, the GPRA pathway is involved in the regulation of immune
functions of asthma. GPRA gene variants may affect the individual risk for airway
hyperresponsiveness in susceptible persons.
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